Weight Management

Weight Management

Last updated: 08/2020

Contributor(s): Dr. Maureen Williams, ND; Dr. Corey Schuler, RN/MS/DC/LN/CNS/CNSC/MBA; Debra Gordon, MS

1 Overview

Summary and Quick Facts

  • If overweight, shedding pounds is one of the most important things to do. The problem is that most diets don’t address underlying factors that make it difficult to lose weight.
  • This protocol will explain the many underlying factors to address, if looking to lose weight. Learn how to approach weight loss with an arsenal of complimentary diet and exercise habits, medication strategies and dietary supplements that target specific mechanisms to restore a healthy metabolism.
  • This comprehensive approach to weight loss could help you slim down and improve many biomarkers of health.
  • One key weight loss strategy is to support a healthy rate of carbohydrate digestion and absorption by targeting enzymes in the digestive tract. L-arabinose and specialized extracts of Phaseolus vulgaris target these enzymes.

Why is it Important to Maintain a Healthy Body Weight?

Obesity is a multifaceted chronic disease characterized by excess body fat and increased body weight. Obesity impacts all aspects of physiology, and is associated with increased risk of most major chronic health conditions, including type 2 diabetes, cardiovascular disease, and some cancers. It is also associated with reduced life expectancy.

Alarmingly, the prevalence of obesity is increasing around the world, and the United States has one of the highest rates.

Why is it so Difficult to Lose Weight?

Many people mistakenly believe that weight gain and obesity can be easily resolved with simple adjustments to the energy equation: less energy in (as calories), more energy out (as exercise). While calorie reduction and regular exercise are key components of a healthy weight loss program, the complex nature of weight management and obesity makes successful weight loss extremely challenging.

Many factors influence bodyweight regulation:

  • Intrinsic factors such as:
    • Genetics and epigenetics
    • The complex biology of adipose tissue
    • Adipokine signaling
    • Appetite regulation pathways
    • The microbiome
    • Insulin sensitivity
    • Circadian rhythms
    • Hormones
  • Extrinsic factors such as:
    • Diet
    • Exercise
    • Lifestyle
    • Stress

Habits Associated with Sustained Weight Loss

Many people find long-term maintenance of weight loss is the most difficult aspect of successful weight management. With this in mind, researchers have collected observations regarding the habits and behaviors of individuals who are able to avoid weight regain. In general, successful and sustained weight loss has been correlated with the following:

  • Eating a low-calorie diet that is
    • High in fiber
    • High in low-density foods such as fruits and vegetables
    • Moderate-to-high in protein
    • Low in fat
  • Avoiding sweetened drinks
  • Avoiding refined carbohydrates
  • Eating breakfast
  • Avoiding nighttime eating
  • Having regular daily meals
  • Avoiding snacks
  • Engaging in regular exercise
  • Getting adequate sleep (and maintaining a healthy circadian rhythm)
  • Self-monitoring body weight
  • Receiving support from those close to you
  • Healthy Stress Management

Medical Approaches to Weight Loss

The mainstay of weight loss therapy is calorie reduction and exercise. Counseling, whether in individual or group sessions, increases the long-term efficacy of a lifestyle-based approach to weight loss by emphasizing strategies for maintaining adherence; however, for those with obesity or weight-related health problems, medical interventions may be a consideration. These include:

  • Drug Therapies
    • Phentermine and other appetite suppressants
    • Phentermine-topiramate
    • Orlistat
    • Liraglutide
    • Naltrexone-bupropion
    • Metformin
    • Acarbose
  • Emerging/Investigational Anti-Obesity Drugs
    • Sodium-glucose co-transport inhibitors
    • Beta-3 adrenergic receptor agonists
    • Monoamine reuptake inhibitors
  • Bariatric Devices
    • Gastric balloons
    • Vagal nerve blockade
    • Gastric emptying systems
    • Gastric artery embolization
  • Bariatric Surgeries
    • Sleeve gastrectomy
    • Roux-en-Y gastric bypass
    • Laparoscopic adjustable gastric band

Integrative Interventions to Support Healthy Weight Loss

White kidney bean extract. A meta-analysis that included 11 clinical trials (including some unpublished data from supplement manufacturers) with a combined total of 573 participants found white bean extract, at a dose of at least 1,200 mg per day for a minimum of four weeks, promoted weight loss in overweight and obese individuals.

Saffron. In a study of 60 healthy, mildly overweight women on an unrestricted diet, 176.5 mg saffron stigma extract daily for eight weeks produced an average weight loss of about 2 pounds. Much of this weight reduction was attributed to a reduction in snacking frequency.

Thylakoids. Thylakoids are components of plants that participate in plant metabolism. Studies have found that thylakoid ingestion by humans and some animal models helps reduce food cravings and may promote healthy weight loss.

DHEA and 7-Keto DHEA. Dehydroepiandrosterone (DHEA) is an adrenal steroid hormone and a precursor to the sex steroids testosterone and estrogen. In a randomized controlled trial in 125 elderly men and women, 50 mg DHEA daily for two years lowered visceral fat mass, improved glucose tolerance, and decreased levels of inflammatory cytokines.

Irvingia gabonensis. Extracts of the seeds of Irvingia gabonensis, a mango-like West African fruit, may reduce body fat and promote healthy blood lipid and fasting blood glucose levels.

Gynostemma pentaphyllum. Compounds extracted from gynostemma have been shown to activate adenosine monophosphate-activated protein kinase (AMPK), a critical enzyme that regulates cellular metabolism and other cell functions. In a randomized placebo-controlled trial that included 80 participants with obesity, 450 mg gynostemma extract per day for 12 weeks resulted in decreased body weight, total abdominal fat area, body fat mass, percent body fat, and BMI.

Whey protein. A meta-analysis of nine controlled trials determined whey protein not only enhanced weight and fat loss, it also decreased cardiovascular risk by improving lipid levels, blood glucose levels, and blood pressure.

2 Introduction

Obesity is a multifaceted chronic disease characterized by excess body fat and increased body weight. Metabolic dysfunction, due to unhealthy expansion of fat tissue, is the hallmark of obesity and its complications.1,2 Abdominal obesity is the most commonly occurring component of metabolic syndrome—a group of interrelated risk factors for type 2 diabetes and cardiovascular disease (central obesity, high blood pressure, high cholesterol and triglyceride levels, and high blood glucose levels).3

There are multiple contributing causes of obesity and metabolic disturbance, encompassing such complex factors as human behavior and neuropsychological drivers, environmental conditions, genetics and epigenetics, hormonal and inflammatory signaling, and the microbiome.4-6 As a metabolic disease, obesity impacts all aspects of physiology. Obesity is associated with increased risk of most major chronic health conditions, including type 2 diabetes, cardiovascular disease, and some cancers. It is also associated with reduced life expectancy.4,5

Alarmingly, the prevalence of obesity is increasing around the world, and the United States has one of the highest rates.7 Based on the most current data collected through the ongoing National Health and Nutrition Examination Survey (NHANES), the Centers for Disease Control and Prevention reports obesity is more prevalent now than ever in the United States, affecting about 40% of adults and 18.5% of youth. The numbers are highest in those 40–59 years of age, and higher in women than men at every age.8 Nearly half of US adults are projected to be obese by 2030.9

A comprehensive approach to healthy weight loss includes a healthy diet, regular physical activity, and social support. This strategy may be enhanced by integrative interventions that target various pathways which can support metabolic health.10-12 In some cases, medications and surgery are considerations.

This protocol explores the most current scientific understanding of obesity. It also presents the scientific evidence for various dietary and lifestyle-oriented weight loss strategies, and evaluates the role of supplements in an integrative weight loss program. Well-supported nutritional supplements, including green tea, green coffee bean, chromium, whey protein, and probiotics, are further described.

3 Background

The Importance of Weight Loss

Excessive weight gain changes body composition by increasing fat tissue mass. This can lead to a cascade of disordered metabolic signaling that culminates in diseases such as diabetes and cardiovascular disease.13 Overweight and obesity are associated with a host of health problems related to mechanical and metabolic stresses, including osteoarthritis, type 2 diabetes, stroke, coronary artery disease, and cancer. As a result, individuals with obesity are more likely to die prematurely than their normal weight counterparts.14,15 On the other hand, weight loss is associated with many health improvements. Just 5–10% of body weight loss through dietary interventions can reduce fat mass, triggering positive changes in metabolism and lowering risks of metabolic disorders. The benefits are even greater with at least 15% of body weight loss.14

Many people mistakenly believe that weight gain and obesity can be easily resolved with simple adjustments to the energy equation: less energy in (as calories), more energy out (as exercise). While calorie reduction and regular exercise are key components of a healthy weight loss program, the complex nature of weight management and obesity makes successful weight loss extremely challenging.

Metabolism and Energy Balance

Metabolism, in simplest terms, is the entire process of transforming nutrients into energy. The macronutrients of food, namely protein, carbohydrate, and fat, are broken down and can be converted into energy. That energy is either consumed in the process of digesting food and moving nutrients, used to run the ordinary workings of the body’s cells and tissues at rest, or used to fuel physical activity.16,17 The total amount of energy a body uses over time to support all of these functions is sometimes called metabolic rate. The energy used by the body at rest is known as resting energy expenditure and is the largest contributor to metabolic rate, accounting for 60–75% of total energy expenditure.16,18

Resting Energy Expenditure

Resting energy expenditure (REE) is not static, but rather subject to the adaptive mechanisms in the body that resist changes in weight and fat mass. For example, when calorie intake is reduced, the body compensates by decreasing REE. However, regular exercise increases REE, in part due to the higher metabolic activity of muscle compared with fat, so it is important to couple dieting with exercise.18

Energy Balance

When energy intake exceeds overall energy demand, signals from insulin and other metabolic regulators trigger nutrient uptake and storage. Tissues such as the liver and muscles have limited capacity to store glucose as glycogen, but fat tissue has virtually unlimited capacity to store excess energy as fat.19 When energy intake is less than the body requires, fat stores are generally preserved until glucose stores are depleted.20 Fat is the most efficient and abundant source of stored fuel, and our fat stores allow us to maintain long-term energy balance.19,21 However, the balance between energy intake and overall energy expenditure is also malleable, and multiple factors, including composition of the diet, timing of eating, and timing and intensity of physical activity, influence how stored energy is used.16,19,20

Overcoming the body’s adaptive mechanisms for preserving body weight and fat mass is essential for an effective healthy weight loss program. In fact, metabolic adaptation to weight loss is estimated to account for 50% of the discrepancy between expected and actual weight loss in individuals with obesity on weight loss programs.22

“Metabolically Healthy” Obesity

A large number of obese individuals have overt metabolic disease, such as type 2 diabetes or cardiovascular disease, or have multiple signs of metabolic dysfunction, such as high triglyceride levels, disordered cholesterol levels, high glucose levels, high blood pressure, and/or evidence of insulin resistance. But a substantial subset of obese individuals show no or few such signs, and are often referred to as the “metabolically healthy” obese.23,24 Because this term has no official definition, estimates of the prevalence of metabolically healthy obesity vary. One report examined the findings from 40 studies and determined that, among obese individuals without overt metabolic disease, approximately 35% are metabolically healthy.25

Unfortunately, long-term studies indicate 30–50% of people with “metabolically healthy obesity” gradually progress to a metabolically unhealthy state.23,25 Furthermore, although metabolically healthy obese individuals have lower rates of type 2 diabetes, cardiovascular disease, and death from any cause than their metabolically unhealthy counterparts, they still are at higher risk of developing metabolic abnormalities (eg, elevated blood pressure and abnormal blood lipid profile) compared with normal-weight people with good metabolic health.23-25

Researchers have found that, compared with obese individuals who are metabolically unhealthy, those who are metabolically healthy are more physically active and have better cardiorespiratory fitness.26 There is also growing evidence that dietary factors such as low consumption of sugar and sugary beverages and high intake of whole fruit, whole grains, and vegetable protein are associated with better metabolic health in obese subjects.23 Differences in gut microbiome and genetic factors affecting fat tissue function may also play important roles in determining metabolic health status in people with obesity.27,28

4 Intrinsic Factors Related to Body Weight Regulation

The Genetics and Epigenetics of Body Weight Regulation

Many people believe their body weight or inability to lose weight is “genetic.” In fact, genetics does play a substantial role in some aspects of body weight regulation. For example, certain variations of genes related to leptin receptors have been found to be associated with increased susceptibility to obesity.29

In recent years, researchers have become increasingly interested in the role of epigenetics in body weight regulation. Epigenetic factors regulate the way genes are expressed without altering the underlying genetic code; essentially, epigenetics has to do with how genes are turned on and off. Unlike the genetic code, which is for the most part unchangeable, epigenetic modifications are influenced by environmental factors, including diet and lifestyle choices, as well as life experiences and exposures. Epigenetic changes occur during a lifetime and to some extent can be passed on to offspring.30

Much of the epigenetic programming that affects us throughout life occurs before we are born. Some of the first evidence of this comes from observational studies in which children born to mothers who experienced famine during the Second World War were prone to obesity later in life. Even grandchildren of famine-exposed women have been found to have high rates of overweight and obesity demonstrating the heritability of epigenetics.31 Maternal obesity, as well as metabolic disease in fathers, have also been found to cause epigenetic alterations favoring obesity and metabolic disturbances in children.32 It is now known that epigenetics affect the levels and actions of key appetite regulators such as leptin.33

Evidence from animal and human studies suggest overeating, a Western-style high-fat/high-sugar diet, sedentary lifestyle, and exposure to environmental stimuli referred to as endocrine disrupters may contribute to epigenetic alterations related to obesity and metabolic disease risk.29,30,34,35 On the other hand, calorie restriction without malnutrition, polyphenols from plant foods, and physical activity can trigger epigenetic modifications that support healthy body weight and metabolic regulation.35-37

The Complex Biology of Adipose Tissue

Adipose tissue and metabolism. Many problems associated with obesity begin in the adipose (fat) tissue. Adipose tissue is an organ, releasing hormones and other cell-signaling molecules that interact with the immune system and participate in regulating energy storage and use throughout the body.1 Its main function is to store fatty acids and other lipids during times of energy excess (after eating) and release fatty acids to be used for energy production during times of energy deficit (fasting).21,38 Adipose tissue also helps regulate body temperature and provides mechanical cushioning in some parts of the body.21

Adipose tissue expansion. Adipose tissue undergoes expansion and remodeling in response to calorie intake. In healthy conditions, excess calorie intake triggers an increase in the number of fat cells and their responsiveness to insulin. In unhealthy conditions, especially when excess calorie intake is chronic, fat cells increase in size as they accumulate more fatty acids, but their numbers diminish. The remaining enlarged fat cells become increasingly resistant to insulin and release inflammatory signals that initiate and perpetuate a cycle of tissue damage and chronic inflammation. This transformation of adipose tissue may lead to a condition known as lipotoxicity,39 in which fat cells that are no longer able to respond to insulin release fatty acids and cholesterol that accumulate on the surfaces of organs such as the liver and heart, triggering more inflammatory signaling and further reducing insulin sensitivity. The result is a systemic metabolic disturbance that can lead to type 2 diabetes, cardiovascular disease, and many other chronic ailments.1,21

Visceral and subcutaneous adipose tissue. Whether or not adipose tissue becomes metabolically unbalanced depends in part on where it is located. Higher amounts of visceral adipose tissue, which is distributed around body organs, are more closely associated with inflammatory and metabolic disorders. Subcutaneous fat, which is present under the skin, is less likely to be associated with inflammatory and metabolic disruption; however, excess subcutaneous fat can still be problematic, particularly when it accumulates in the abdomen.1,40

White, brown, and beige adipose tissue. There are two main types of adipose tissue: white and brown. Brown adipose tissue is made up of fat cells that are rich in mitochondria and specialized for heat generation (thermogenesis), while white adipose tissue cells are more involved in metabolic activity.21 A third type of adipose cell has recently been discovered within the white adipose tissue. Known as beige or brite (brown and white) cells, these newly identified fat cells appear to have more flexibility in their function, and can be induced to increase their thermogenic activity through a process referred to as browning.41 Conditions that activate the sympathetic or “fight or flight” aspect of the nervous system, such as exposure to cold temperature and extreme physical stress, increase the size and activity of brown adipose tissue and stimulate browning of white adipose tissue.41,42 Hormones including thyroid hormone, insulin, leptin, and melatonin have all been shown to induce browning.43 Other factors that may influence browning include diet, fasting, exercise, genetic and epigenetic factors, and the composition of the gut microbiome.38,42

Brown adipose tissue has been shown to be an important contributor to REE in animal models, but the contribution of brown adipose tissue to energy expenditure in humans is less well established. Higher amounts and activity of brown adipose tissue have been associated with healthier blood glucose control, insulin sensitivity, fat distribution pattern, and body weight in human studies.38,41 Strong inflammatory signaling associated with obesity, however, can impair brown and beige fat cells’ ability to take up glucose and produce heat.44


Adipokines are cell-signaling molecules released by adipose tissue that affect both local and distant target tissues. Adipokines serve as a link between obesity and inflammation, and thus are critical in the development of obesity-related complications.45 Levels of adipokines are related in part to the distribution and types of fat tissue in the body.45 Adipokines not only impact inflammation and metabolic processes, but also help regulate appetite and body weight, and are often a target of weight loss strategies.38,45

Perhaps the best known adipokines are leptin and adiponectin, which are produced by all types of adipose cells. In healthy conditions, leptin’s pro-inflammatory effects are balanced by adiponectin’s anti-inflammatory effects.46 High leptin and low adiponectin levels are associated with obesity and its complications, including type 2 diabetes, cardiovascular disease, and cancer.

Leptin. Despite its role in promoting inflammation, leptin has positive effects on metabolism such as enhancing insulin sensitivity, promoting white adipose browning and thermogenesis, increasing glucose uptake by cells, and reducing blood lipid levels.40,43 Importantly, leptin also suppresses hunger. As part of an evolutionary defense against excessive weight loss, leptin release declines as fat mass diminishes; unfortunately, this adaptive mechanism interferes with healthy weight loss in people with overweight and obesity.47 In addition, despite high leptin production in response to overeating, leptin responsiveness becomes blunted in those with obesity and insulin resistance, such that high circulating leptin levels lose their impact on appetite and metabolism, resulting in a state described as leptin resistance.33,40,47

Adiponectin. Adiponectin is important for healthy cellular metabolism and insulin sensitivity.48 It also helps maintain healthy vascular function and inhibits formation of certain tissue-damaging free radicals. Adiponectin levels increase with fasting and exercise but decrease with overeating. In addition, dysfunctional obesity-related adipose tissue conditions such as hypoxia (low oxygen availability due to enlarged adipocyte size), increased inflammatory signaling, and high oxidative stress reduce adiponectin release.40,48

Irisin. Another adipokine, irisin, has recently attracted attention for its role in the browning of white fat. Irisin is a protein produced by white adipose tissue, as well as muscle tissue, and promotes thermogenesis.45

Appetite Regulation

Appetite and food intake are controlled by interplay between physiologic mechanisms and external factors.

Physiologic mechanisms. Appetite-suppressing signals, also known as satiety signals, are facilitated by the hormones leptin (secreted by adipose tissue) and insulin (secreted by the pancreas), as well as peptides produced in the brain; appetite-enhancing signals come from the brain peptides (known as neuropeptide Y and agouti-related peptide) to help maintain a balance between energy demands and availability.49,50 The neurotransmitters GABA, serotonin, and oxytocin appear to influence behaviors related to eating.50 In addition, the gut produces signaling molecules that alter appetite, such as cholecystokinin, which helps curb eating once the stomach is full, and ghrelin, which counterbalances the effects of leptin by stimulating appetite and eating.49,50 This complex network of signals governs your desire to eat and motivation to modify behavior accordingly.50

The sensitivity of the neural pathways involved in appetite is greatly affected by genetic and epigenetic factors.49 In obesity, signaling along these appetite-regulating pathways are generally diminished, which can make control over eating behaviors extremely difficult.50

Ghrelin. Ghrelin is a hormone produced mainly in the empty stomach with functions that overlap with those of adipokines. Ghrelin stimulates eating through complex effects in the brain, where it increases the drive to eat, enhances a sense of well-being from eating, modulates taste and smell, and upregulates food-seeking behavior.51 It also contributes to regulating gut motility and digestive function, and has a range of metabolic effects, such as suppressing thermogenesis in brown adipose tissue; stimulating fat production and storage; and reducing insulin release and raising blood glucose levels.52 Obesity has been linked to dysfunctional overproduction of ghrelin. Calorie reduction and weight loss further raise ghrelin levels, adding to the difficulty of achieving healthy weight loss.53

Insulin Resistance and Metabolic Syndrome

Insulin resistance and obesity are related conditions that often occur together. Insulin is a key metabolic hormone produced in the pancreas in response to high nutrient availability. In healthy conditions, insulin increases glucose uptake by cells, which store excess glucose as glycogen or fat, and prevents glucose generation while stimulating lipid production by the liver.54 In unhealthy conditions, including those caused by a high-calorie, nutrient-poor diet, low-level inflammation causes fat cells to become increasingly resistant to the effects of insulin. As insulin resistance progresses, levels of both insulin and glucose rise, and adipose tissue releases free fatty acids into circulation.54,55 These excess fatty acids then accumulate in organs that are not equipped to process and store extra fat. This abnormal deposition of fat is known as lipotoxicity, a condition that causes tissue and organ dysfunction and accelerates widespread inflammatory signaling, insulin resistance, and poor vascular function.1,39,54

Because insulin-resistant tissues generate high levels of tissue-damaging free radicals and instigate chronic low-level inflammation, insulin resistance has been suggested to be an important link between chronic metabolic and inflammatory disorders.56 Long-term overeating and a high-fat, Western-type diet have been shown in many studies to raise the risk of insulin resistance and obesity (particularly in the abdomen), as well as high cholesterol and triglyceride levels and high blood pressure.57 This cluster of related conditions, which often occur together and contribute to a higher risk of type 2 diabetes and cardiovascular disease, are called metabolic syndrome.3,56 People with metabolic syndrome also have increased risks of neurological diseases, liver cirrhosis, autoimmune diseases, and some cancers, as well as death from all causes.58,59

The Role of the Microbiome

The community of microorganisms that inhabit the intestines, referred to as the gut microbiota, is increasingly being recognized as an important regulator of such fundamental body processes as digestion, immune function, metabolic function, behavior, mood, food preference, and appetite.6,60 Gut microbes make many nutrients from our food more accessible, produce fermentation by-products, and send and receive signals from tissues and cells throughout the body, including the brain. The microbes and their surrounding environment are collectively called the microbiome. Through its communication networks, the microbiome is thought to modulate genetic expression, or epigenetics, and thus profoundly influence health.61-63

A Western-type diet can alter the microbiome in ways that may then lead to obesity by triggering changes in cognition, mood, and the drive to eat, as well as expression of proteins that control metabolism.6,62 Factors such as changes in cycles of sleep, timing of eating, or time zone can alter the microbiome composition and disrupt circadian interactions between the microbiome and the body’s innate systems, increasing the risk of metabolic disturbance and weight gain.64 Imbalances of gut bacteria, or dysbiosis, might further contribute to weight gain, obesity, and other metabolic disorders by amplifying inflammatory immune activity, enhancing faulty adipose tissue expansion, and contributing to insulin resistance.61,63,65

Findings from the Human Microbiome Project show that people with obesity typically have microbiomes with less bacterial diversity overall, as well as more Firmicutes bacteria and less Bacteroidetes bacteria, compared with lean people. As Firmicutes possess more genes for enzymes involved in the metabolism of carbohydrates and fats than Bacteroidetes, generally speaking, Firmicutes bacteria are capable of facilitating more efficient extraction of energy from food, thus inducing more fat accumulation than Bacteroidetes bacteria.66,67 Although not all studies have been able to observe this obesity-related microbiome pattern,65 there is ample evidence that supporting a healthy microbiome is an important facet of a healthy weight loss program.

Circadian Rhythms and Metabolism

The human circadian clock (a complex network of feedback loops that modulates physiological systems in daily cycles) is an important regulator of virtually every biological system in the body and is recognized as a key factor affecting metabolism and body weight.68,69 Central circadian control occurs in the brain and is primarily affected by light and dark cycles, but peripheral circadian system tissues respond to cues such as temperature, hormone and neurotransmitter levels, and certain nutrients, as well as sleeping, eating, and physical activity patterns.70,71 These peripheral circadian networks can become misaligned with the central circadian clock in people affected by sleep disturbance, nighttime light exposure, shift work, jet lag, nighttime eating, and other nighttime activity. Circadian desynchronization can then lead to fundamental disturbances of glucose and lipid metabolism and energy balance, and is associated with weight gain and metabolic disorders.64,68,71

Insulin sensitivity has been shown to have a circadian cycle, peaking in the morning and diminishing as the day progresses; therefore, the timing of food intake alters its glycemic effects.69,71 Adipose tissue is responsive to circadian signals, releasing adipokines in a rhythmic pattern. For example, levels of leptin, an adipokine that quiets the appetite and increases thermogenesis, peak at night; however, conditions and behaviors that desynchronize the circadian system may disrupt leptin release and contribute to loss of normal energy balance.70

The gut microbiome is an important link in the human circadian system. Daily rhythms have been noted in microbiome composition and function, and these cycles affect metabolic activity in the body. Behaviors that contribute to weight gain, such as consuming a high-fat Western diet, overeating, and nighttime eating, may exert their unhealthy effects partly by disrupting the healthy rhythms of the microbiome.64 In addition, conditions that alter the microbiome, such as use of some medications and diseases of the digestive tract, may contribute to poor sleep and metabolic problems by triggering circadian misalignment.72

Thyroid and Sex Hormones

Thyroid and sex hormones can also affect the body’s propensity to preserve or lose weight.

Thyroid hormones. Hormones produced in the thyroid gland increase total energy expenditure by targeting cellular metabolism and energy production capacity, and contribute to weight control mechanisms through their actions on appetite, adipose tissue signaling, and the brain.73-75 The main thyroid hormones are thyroxine (T4) and its active metabolite triiodothyronine (T3). Under stimulation by a hormone from the brain called thyroid stimulating hormone (TSH), the thyroid gland releases mainly T4, which is converted to T3 in other tissues.76 The conversion rate of T4 to T3 has been found to be lower in those who have lost even a modest amount of weight, exemplifying the various innate mechanisms for preserving energy balance.75 People with hypothyroidism are prone to weight gain and appear to have difficulty increasing their energy expenditure to support exercise.77 It is important to test thyroid function in those struggling to lose weight, since treatment with thyroid hormone replacement therapy may be helpful in some cases75; however, thyroid hormone therapy is not safe for treatment of overweight and obesity in people with normal thyroid function.74,76

Estrogens and progesterone. Changes in female hormone levels throughout life contribute to well-known changes in metabolism. Higher estrogen levels in reproductive aged women favor subcutaneous fat accumulation, especially in the hips and thighs; conversely, after estrogen levels drop at menopause, women tend to accumulate central and visceral fat and lose muscle. The changes in body composition and fat distribution associated with estrogen loss are linked to metabolic disturbance and increased cardiovascular risk.78 Estrogen also stimulates thermogenesis in brown adipose tissue, increasing total energy expenditure. A post-menopausal decrease in energy expenditure due to reduced estrogen-related thermogenesis may contribute to weight gain.79

Estrogens have been found to reduce sweet cravings and decrease appetite, possibly by increasing sensitivity to fullness signals from cholecystokinin. Progesterone, on the other hand, has little effect on metabolism but may increase eating, particularly during times of emotional stress. It is thought progesterone may enhance food-induced activation of reward pathways in the brain.80 Studies have shown calorie intake decreases during the first half of the menstrual cycle to a minimum around ovulation and then rises to a maximum around menstruation, possibly due to fluctuations in estrogen and progesterone levels.81 After menopause, estrogen replacement therapy may be beneficial for preserving healthy body composition and adipose tissue distribution, but these potential benefits must be weighed against possible increased risks of stroke and breast cancer.78,82 For additional information, refer to Life Extension’s Female Hormone Restoration protocol.

Androgens. Male hormones, or androgens, support muscle mass and normal insulin sensitivity, and low levels of testosterone, the main androgenic hormone, are associated with visceral obesity and metabolic syndrome in men.83,84 Body composition and metabolic health have been noted to undergo negative changes as androgen levels decline with age. Testosterone replacement has been shown to have metabolic and other benefits in older men with testosterone deficiency.84

Dehydroepiandrosterone (DHEA) is an androgenic hormone produced in the adrenal gland. DHEA production drops gradually with age. A study in 13 female twin pairs, 10 of which had substantial differences in body weight between co-twins, found having higher DHEA levels was associated with lower body weight and percent body fat.85 Findings from animal research suggest lower DHEA levels may be associated with weight gain, muscle loss, and increased fat mass, as well as insulin resistance and other negative metabolic changes.86,87

5 Extrinsic Factors Related to Bodyweight Regulation

External conditions around eating, such as caloric density and portion size, and setting and social environment, can influence appetite and amount of food eaten.50 For example, eating at home and family dinners have been associated with healthier food intake and lower risk of overweight and obesity, whereas watching television during meals is correlated with unhealthy eating and increased risk of obesity.88,89 The ways these conditions influence appetite and weight loss varies greatly between individuals.90

Lifestyle can influence appetite control. Unfortunately for those trying to lose weight, calorie restriction and weight loss enhance appetite signaling, increasing the desire to eat. Combined with weight loss-associated changes in energy expenditure, the result is often inability to lose more weight or weight regain.90 In those eating a high-calorie, high-fat diet, free saturated fatty acids can cross the blood-brain barrier and trigger inflammation in parts of the brain that, among other things, regulate appetite. These brain areas, like other parts of the body, then become resistant to signals from insulin and leptin.49 On the other hand, short bouts of exercise can suppress appetite in the short term, and habitual exercise appears to improve sensitivity to the appetite-regulating system.91

Stress is one of the most important external factors affecting appetite and eating behaviors. Although the response to stress is highly individualized, in general, acute stress is associated with high levels of catecholamine neurotransmitters that reduce appetite, while chronic stress is usually associated with high levels of cortisol, a hormone that appears to promote a selective appetite for high-calorie palatable foods.92 Often referred to as comfort foods, they are typically high in sugar and fat, and can stimulate reward pathways in the brain that reduce stress reactivity and may relieve negative emotions associated with stress. This may explain in part how stress can induce overeating of high-calorie foods,92,93 and highlights the importance of stress management as part of a healthy approach to weight loss. For additional information, see Life Extension’s Stress Management protocol.

6 Assessing Body Composition

The most commonly used measure for identifying overweight and obesity is body mass index, or BMI. BMI is calculated by dividing body weight in kilograms by height in meters squared. Because it does not distinguish between fat mass and lean muscle mass, nor take into account body fat distribution, BMI is limited in its usefulness5,94; nevertheless, it has been shown to be reasonably closely correlated with more definitive measures of visceral fat, such as computed tomography (CT) and magnetic resonance imaging (MRI), and with obesity-related complications.5 Although these cutoff values may vary with ethnicity, according to the Centers for Disease Control and Prevention, an American or European adult with a BMI95:

  • <18.5 kg/m2 is considered underweight;
  • between 18.5 and 24.9 kg/m2 is considered normal weight;
  • between 25 and 29.9 kg/m2 is considered overweight;
  • 30 kg/m2 or higher is considered obese; and,
  • >40 kg/m2 is considered extremely or severely obese.

Abdominal fat is a stronger predictor of metabolic disease than body weight; therefore, assessment tools that take abdominal size into account better reflect health status with regard to overweight and obesity. Waist circumference and waist-to-height ratio (waist circumference divided by height) both correlate well with percent body fat and metabolic disease risk. With strong evidence for its usefulness and simplicity of measurement, waist circumference is now included among the diagnostic criteria for metabolic syndrome.96 In general, a waist circumference of ≥40 inches (102 cm) in men or ≥35 inches (88 cm) in women is considered indicative of high metabolic risk. Waist-to-height ratio may be slightly more accurate than waist circumference and BMI, and has the added advantage of a single reference for people of all ages: a ratio of ≥0.5 is widely accepted as indicative of central obesity in children ≥6 years old as well as adults.94,97,98

A study that included 1,856 men and women between 46 and 73 years old used more than a dozen blood tests as well as blood pressure and body measurements to assess metabolic health. Comparing metabolic health status to BMI and waist-to-height ratio, the study showed that a combined assessment of BMI and waist-to-height ratio provided the most accurate reflection of metabolic health.99 Similarly, a study done in Singapore found participants with both a BMI ≥23 kg/m2 and waist-to-height ratio ≥0.5 had the highest cardiovascular risk.100

7 Lab Tests That May Inform Your Weight Loss Plan

In addition to measures of body size and composition, certain blood tests can help identify underlying causes and evaluate metabolic health status in people who may be overweight or obese.



OPTIMAL RANGE (LabCorp Methodology)

Total cholesterol

100–199 mg/dL

160–180 mg/dL


0–99 mg/dL

<80 mg/dL


>39 mg/dL

≥50 mg/dL


<150 mg/dL

<80 mg/dL

Hemoglobin A1c (HbA1c)



Fasting glucose

65–99 mg/dL

70–85 mg/dL

Fasting insulin

2.6–24.9 μIU/mL

<5 μIU/mL

C-reactive protein (CRP, high sensitivity)

Low risk: ≤1.0 mg/L

Men: <0.55 mg/L

Women: <1.0 mg/L


Established by lab and varies with body composition


Men age 20–24 years:

164–530 μg/dL

Women age 20–24:

110–432 μg/dL


350–500 μg/dL


275–400 μg/dL

Total testosterone


264–916 ng/dL


8–48 ng/dL


700–900 ng/dL


35–45 ng/dL

Free testosterone

Men age 20 – 29:

9.3–26.5 pg/mL


0.0–4.2 pg/mL


20–25 pg/mL


2.1–4.2 pg/mL



7.6–42.6 pg/mL


Premenopausal: variable


<6.0–54.7 pg/mL


20–30 pg/mL


Premenopausal: variable



30–100 pg/mL



Premenopausal: variable


0.1–0.1 ng/mL (without hormone replacement)



15–23 ng/mL



2–6 ng/mL (with hormone replacement)

Thyroid stimulating hormone (TSH)

0.4–5.0 μIU/mL

May be age-dependent; Should be interpreted in the context of other thyroid parameters; 1–2 μIU/mL has been associated with higher metabolic rate than higher levels in some studies

Free thyroxine (T4)

0.82–1.77 ng/dL

1.46–1.77 ng/dL

Free triiodothyronine (T3)

2.0–4.4 pg/mL

3.4–4.2 pg/mL

8 Dietary and Lifestyle Approaches to Weight Loss

The most constant feature of all effective weight loss diets is they are low in calories.101 Beyond that, popular weight loss diets vary considerably in terms of macronutrient composition, specific foods recommended, and timing of eating. These differences are purported to alter the fundamental mechanisms of weight control: energy balance, fat tissue signaling and widespread inflammation, insulin sensitivity and blood glucose control, appetite signaling, health of the microbiome, epigenetics of metabolism, and alignment with circadian rhythms. However, whether a diet will result in weight loss depends largely on individual characteristics that influence our response to dieting. Such characteristics are still poorly understood, but may be partly related to genetics. It is important to note that not all weight loss diets, even if they work, improve long-term health.

Altering Macronutrient Intake

Marketing campaigns associated with various weight-loss-oriented diet programs claim the diet in question can influence energy expenditure and appetite signaling, making weight loss easier and more effective, through manipulation of the proportions of macronutrients—carbohydrate, protein, and fat.102 However, this is a contentious area of active debate and investigation among the nutrition research community. Below we present several common dietary approaches and discuss the evidence for their efficacy.

Low-fat diets. The low-fat diet, popularized by Dean Ornish, MD in the 1980s, was introduced as a cornerstone of a holistic approach to preventing and reversing heart disease. The Ornish diet, which is plant-based and derives ≤10% of calories from fat, emphasizes whole, unrefined foods and incorporates large amounts of low-calorie-density, high-nutrient foods like fruits and vegetables.103 Research has shown that restricting saturated fat may be more important than total fat, and dietary fat reduction has metabolic benefits only if fat calories are not replaced with carbohydrates, particularly processed carbohydrates such as starches and sugars.104,105

Dietary Approaches to Stop Hypertension, or DASH, is a less restrictive low-fat diet in which no more than 30% of calories are from fat. It also limits intake of saturated fat, cholesterol, refined carbohydrates, sugars, and sodium. DASH has been found to lower cardiovascular risk and blood pressure, promote weight loss, and reduce risk of type 2 diabetes. 106 A meta-analysis of 54 trials with a total of more than 30,000 overweight and obese participants found low-fat and low-saturated fat weight loss diets reduced premature mortality, resulting in six fewer deaths per 1,000 participants.107

In general, low-fat diets have similar weight loss effects as other diets with similar daily calorie intake.101 Interestingly, their effects on markers of cardiovascular risk may be different than those of other weight loss diets. A meta-analysis that included 20 studies with a combined total of 2,106 overweight and obese participants found low-fat diets improved total and LDL-cholesterol levels more than high-fat diets, but high-fat diets improved HDL-cholesterol and triglyceride levels more than low-fat diets.108 The possible implications of these differences for long-term health outcomes is still not clear.

Ketogenic or “keto” diets. Robert Atkins, MD, first proposed his ketogenic high-fat/low-carbohydrate weight loss diet in the 1970s. More recently, low-carbohydrate diets—referred to as “paleo” and “ketogenic” diets—have been popularized. Restricting carbohydrate intake reduces blood glucose and insulin levels and increases fat metabolism, resulting in increased levels of byproducts known as ketone bodies. By regulating glucose levels and stimulating ketosis, this diet may lead to better appetite signaling and glucose metabolism.103,109 In general, low-carbohydrate diets high in fat and/or protein have been shown to induce more rapid weight loss than high-carbohydrate diets; however, to date, researchers have failed to find a significant advantage on long-term weight loss.101,102 Furthermore, high-fat/low-carbohydrate diets have been found to have negative impacts on LDL-cholesterol levels and vascular health in some studies, even while having positive impacts on HDL-cholesterol and triglyceride levels.108,110

Very-low-carbohydrate diets such as the ketogenic diet include no more than 50 grams of carbohydrate per day. They are typically low in fruits, vegetables, and fiber, and rely on calories from animal fat and protein. This may lead to poorer long-term health outcomes.103 In fact, a recent study that followed more than 15,000 adults for about 25 years noted very low carbohydrate intake (<40% of calories from carbohydrates), when accompanied by high intake of animal fat and protein, was associated with a 20% increase in death from any cause. The study also found very high carbohydrate intake (>70% of calories from carbohydrates) was associated with increased mortality, suggesting moderate carbohydrate intake may be optimal for long-term health.111

High-protein diets. Dietary protein reduces appetite, preserves muscle, supports insulin sensitivity, and promotes thermogenesis.102,112 Comparison trials suggest high-protein diets have better short-term weight loss effects than high-carbohydrate diets, but findings from longer studies have been inconsistent.101,102 One meta-analysis of studies found higher protein intake was associated with less weight regain after successful weight loss in overweight and obese subjects.113 This may be due in part to protein’s satiating effect.112,114 It is important to note, however, that high intake of animal protein has been linked to increased risk of kidney stones as well as chronic health problems like heart disease, type 2 diabetes, and cancer. Plant proteins, on the other hand, are not associated with these health problems.102

Artificial Sweeteners and Weight Loss

Many people on weight loss diets use sugar substitutes to reduce their calorie intake while enjoying foods that taste sweet. Artificial sweeteners like aspartame, sucralose, and saccharin have been promoted to diabetics and dieters as healthy sugar alternatives for decades, but their role in metabolic disease now appears to be more complex than previously thought.115 In fact, although the evidence is not conclusive, consumption of artificial sweeteners has been implicated as a possible contributor to the rising rates of obesity and diabetes, and may also be linked to the development of metabolic syndrome.116-118

Sweet-sensitive taste receptors are known to be present in the mouth, gut lining, pancreas, and brain.119 By activating taste receptors throughout the body, artificial sweeteners can alter production of neurotransmitters and hormones that regulate appetite signaling and glucose metabolism, which has been found to trigger metabolic dysregulation in preclinical research.115,119 In addition, animal studies suggest artificial sweeteners can cause inflammation in the digestive lining and alter the gut microbiome, potentially leading to leaky gut, systemic inflammation, and insulin resistance.115,120

Broader Dietary Patterns

Mediterranean diet. The Mediterranean diet is one of the best-supported dietary patterns for long-term metabolic health.106 Although not inherently a weight loss diet, when implemented as a low-calorie diet and combined with exercise, the Mediterranean diet promotes weight loss similar to other diets with similar degrees of calorie restriction, while improving blood pressure, lipid levels, and other markers of cardiovascular risk.121,122 With its emphasis on fruits, vegetables, whole grains, legumes, nuts, and olive oil, and inclusion of modest amounts of seafood, the Mediterranean diet provides abundant polyphenols, mono- and polyunsaturated fats, and fiber. These food components may support mechanisms for weight loss including stimulating thermogenesis, reducing inflammatory signaling, normalizing adipose tissue metabolism, triggering satiety signaling, and improving the health of the gut microbiome.123,124

Plant-based diet. Plant-based diets are associated with lower risks of metabolic disorders, including obesity, type 2 diabetes, and cardiovascular disease, whereas meat consumption is associated with weight gain, higher BMI, and poorer metabolic parameters.125-127 Observational research indicates BMI increases as the amount of animal food in the diet increases, such that BMI is lowest in vegans (those who avoid all animal foods), higher in vegetarians who include dairy, eggs, and/or fish, and highest in non-vegetarians.126 A meta-analysis that included 12 studies with 1,151 overweight and obese participants found vegetarian diets, and especially vegan diets, were associated with greater weight loss than calorie-matched non-vegetarian diets.128 The positive health effects of plant-based diets may be due to the inherently high nutritional quality of most plant-based diets, which typically include more fruits, vegetables, and fiber than omnivorous diets.127,129 Strict vegans should consider supplementing with vitamin B12 and possibly calcium.129

Intermittent Fasting

Intermittent fasting has recently gained attention as a new strategy for re-establishing healthy metabolic function and losing weight. In addition to reducing total calorie intake, fasting for periods of 12 to 36 hours activates metabolic pathways that promote fat burning and may trigger weight loss without loss of muscle.130

Most intermittent fasting diet plans dictate either time-restricted eating daily or periodic fasts lasting up to 24 hours. One common example of time-restricted eating is fasting for 16 hours each day (usually including overnight) and eating according to appetite for the other eight hours. Prolonged overnight fasting not only reduces total calorie intake but also takes advantage of the body’s circadian rhythms in ways that may further support healthy metabolism. Full-day fasts may be practiced on alternate days or one to two days per week, with very few (such as 25% of usual) or no calories taken on fasting days.130 Despite the theoretical advantages of intermittent fasting, most research comparing it to general calorie restriction have found no differences in weight or body fat reduction.131 Nevertheless, it is noteworthy that some studies have shown time-restricted eating with prolonged overnight fasting naturally results in reduced nighttime hunger, lower overall calorie intake, and weight loss that may be easier to sustain over time.131 In addition, some evidence suggests intermittent fasting may induce less adaptive decline in energy expenditure, possibly leading to better long-term weight management.130

Habits Associated with Sustained Weight Loss

Many people find long-term maintenance of weight loss is the most difficult aspect of successful weight loss. With this in mind, researchers have collected observations regarding the habits and behaviors of individuals who are able to avoid weight regain. In general, successful and sustained weight loss has been correlated with the following11,101,102,132,133:

  • Eating a low-calorie diet that is
    • High in fiber
    • High in low-density foods such as fruits and vegetables
    • Moderate-to-high in protein
    • Low in fat
  • Avoiding sweetened drinks
  • Avoiding refined carbohydrates
  • Eating breakfast
  • Avoiding nighttime eating
  • Having regular daily meals
  • Avoiding snacks
  • Engaging in regular exercise
  • Getting adequate sleep (and maintaining a healthy circadian rhythm)
  • Self-monitoring body weight
  • Receiving support from those close to you


Increasing physical activity during weight loss increases total energy expenditure and reduces the drop in REE triggered by calorie reduction and weight loss. When combined with reduced calorie intake, aerobic exercise has been shown to increase the likelihood of both short- and long-term weight loss.134-136 Exercise has also been found to help preserve muscle mass, promote fat loss, and improve appetite regulation.91 Furthermore, exercise is a critical part of a healthy lifestyle that supports metabolic and overall health; reduces risk of chronic diseases including obesity, type 2 diabetes, cardiovascular disease, and some cancers; and extends lifespan.137 In fact, lack of physical activity has been estimated to be responsible for twice as many premature deaths as obesity.138

Of course, dietary and lifestyle changes work best when used together. In a randomized controlled trial of 147 overweight adults with type 2 diabetes, it was shown that an intensive lifestyle intervention (which included changes to diet and physical activity, and structured lifestyle support) was more effective than usual medical care at reducing body weight, improving glycemic control, and inducing remission of type 2 diabetes. The lifestyle intervention included low-calorie meal replacements in the first phase followed by a gradual reintroduction of food, plus exercise and lifestyle support. Participants in the intervention group lost over three times as much weight as those in the control group during the 12-month study. In addition, 61% of participants in the intervention group experienced remission of their diabetes, compared with only 12% in the control group. The intervention group also had better glucose control.319 It is advisable for people who are overweight to consider implementing both dietary changes as well as a physical activity regimen with the help of their doctor.

Sticking to an exercise regime long-term is a major factor for sustained weight loss.133,134 Therefore, it is important to choose a type of physical activity that is motivating and sustainable. In order to contribute to sustained weight loss, exercise needs to be mainly aerobic, be of at least moderate intensity, and average four to five hours per week in duration. Time spent exercising is cumulative, and therefore is beneficial even when performed in multiple bouts lasting at least 10 minutes.135,136

Attention has focused in recent years on high-intensity interval training (HIIT) as a time-efficient way to achieve the benefits of exercise. Most HIIT protocols involve exercising at >90% of maximum heart rate for repeated short bouts of one to five minutes, with rest or low-intensity activity for several minutes between bouts. HIIT has been found to reduce total and visceral fat mass, even without weight loss.139,140 This is important because fat mass, particularly visceral fat mass, is more closely associated with heart disease than BMI.1,96 HIIT appears to be as beneficial for metabolic health as regular exercise, but has greater effects on fitness.140 A meta-analysis of 18 studies comparing high-intensity exercise, including HIIT, to regular exercise programs involving moderate-intensity activity for longer time periods found high-intensity exercise had the same effects on BMI and waist circumference but resulted in greater reduction in percent body fat than regular exercise. In addition, HIIT led to more improvement in cardiopulmonary fitness than regular exercise.141 For additional information about the benefits of physical activity, including HIIT, refer to Life Extension’s Exercise Enhancement protocol.

Stress Management

One of the greatest challenges faced by people trying to lose weight is dealing with food cravings and the emotional aspects of eating behavior. Stress, depression, and anxiety, as well as external food-related stimuli such as advertisements and ubiquitous food placement, conspire to create a virtually irresistible desire to eat.142 Differences in neurocircuitry in people with overweight and obesity may further add to difficulties controlling food choices and eating behavior. 143,144 Stress management and cognitive behavioral techniques therefore have a potentially important role to play in successful and sustained weight loss.145

Mindfulness-based stress reduction (MBSR) is a validated eight-week stress management program based on cultivating awareness of the present moment. In uncontrolled research, MBSR reduced self-reported emotional eating, binge eating, and eating in response to external cues.146,147 In a controlled trial, subjects who participated in a program teaching mindful eating and prolonged chewing lost more weight, engaged in less emotional- and cue-stimulated eating, and reported fewer cravings compared with matched counterparts placed on a waiting list.148

Cognitive behavioral therapy (CBT), a form of psychotherapy based on developing strategies for coping with unwanted or unhelpful thoughts and behaviors, is another option for managing the psychological aspects of weight loss and eating. CBT has been found to improve weight loss, increase restraint in eating, and reduce emotional eating and binge eating in clinical studies.149,150 CBT may also help decrease the likelihood of weight regain after bariatric surgery.151 For additional information on strategies for managing stress, refer to Life Extension’s Stress Management protocol.

9 Medical Approaches to Weight Loss

The mainstay of weight loss therapy is calorie reduction and exercise. Counseling, whether in individual or group sessions, increases the long-term efficacy of a lifestyle-based approach to weight loss by emphasizing strategies for maintaining adherence; however, for those with obesity or weight-related health problems, medical interventions may be a consideration.152

Drug Therapies

Phentermine and other appetite suppressants. Four stimulants related to amphetamines are approved for short-term use as appetite suppressants in obesity treatment. The most widely used is phentermine (Lomaira); the others are diethylpropion, phendimetrazine , and benzphetamine. Their use is limited to 12 weeks due to potential for tolerance and addiction and frequency of adverse side effects.153,154 Common adverse side effects include insomnia, constipation, and dry mouth; they may also cause high blood pressure, rapid heartbeat, and palpitations.155

Phentermine-topiramate. A combination drug containing phentermine plus the anti-seizure drug topiramate is approved for long-term obesity treatment. Phentermine-topiramate (Qsymia) has been found to induce substantially more weight loss than other medication approaches after one year, resulting in 8.6–9.3% of body weight loss compared with placebo. Unfortunately, it is also associated with more adverse side effects than other weight loss drugs.153

Orlistat. Orlistat (Xenical) interferes with fat digestion and absorption by inhibiting the action of lipase, a fat-degrading enzyme produced by the stomach and pancreas. Its use has been associated with average weight loss of almost 3% of body weight over one to two years.152,153 In addition, orlistat has positive impacts on blood lipid levels, blood pressure, and abdominal fat.156 Orlistat has a good safety profile, but often causes digestive symptoms such as gas, oily stool and discharge, and diarrhea.152,156 Because it reduces absorption of fat-soluble vitamins (A, D, E, and K), people taking orlistat should take a multivitamin supplement.152

Liraglutide. Liraglutide (Saxenda) is an anti-diabetes medication given only by injection that is also used to treat obesity. It has been associated with loss of 4.0–6.1% of initial body weight compared with placebo after one year, and may reduce the risk of type 2 diabetes. 152,156 It has also been found to reduce markers of inflammation and oxidative stress, improve lipid levels, and lower blood pressure, as well as improve cardiovascular outcomes in type 2 diabetics.156 Liraglutide frequently causes diarrhea and nausea, especially in the first few months of use; other possible adverse effects are constipation, indigestion, abdominal pain, headache, fatigue, and low blood glucose levels.152,155

Naltrexone-bupropion. A combination drug containing the opiate blocker naltrexone and the antidepressant bupropion works by reducing the desire to eat. Naltrexone-bupropion (Contrave) was approved for use in obesity treatment in 2014 and has been associated with loss of 2.5–5.2% of initial body weight compared with placebo. Some clinical trials also found it improves glycemic control and lipid levels, but may cause elevated blood pressure and heart rate.156 Nausea is a common side effect and limits its tolerability.152 Other possible side effects include headache, constipation, sleep disturbance, and anxiety.152,155,157

Metformin. Metformin is a blood glucose-lowering drug and is the first-line medication for treating type 2 diabetes. In the decades since its development and approval, metformin use has been associated with a range of metabolic benefits in diabetics, including improvements in lipid levels, nonalcoholic fatty liver disease, cognitive function, cardiovascular risk, cancer risk, and mortality.158 In addition, metformin appears to promote weight loss in people with diabetes by altering appetite regulation and modifying the gut microbiome.158,159 Research in humans and animals indicates treatment with metformin may have a positive impact on gut microbial composition and specifically increase numbers of gut bacteria that produce short-chain fatty acids, which can impact obesity by reducing low-grade systemic inflammation, decreasing the capacity to harvest energy from food, and improving glucose metabolism.160-162

Although some widely used antidiabetic medications, such as insulin, thiazolidinediones (eg, pioglitazone [Actos]), and sulfonylureas (eg, glimepiride [Amaryl], gliclazide [Diamicron], glyburide [DiaBeta], glipizide [Glucotrol]), are known to trigger weight gain, metformin has been found in multiple studies to safely reduce weight in people with diabetes,159,163 including elderly participants,164 and in women with polycystic ovary syndrome.165,166 Clinical trials and observational studies in nondiabetic subjects at risk of diabetes indicate metformin supports weight loss and metabolic health even in the absence of diabetes.167,168 One controlled trial found treatment with metformin for six months resulted in an average weight loss of 5.8 kg (12.8 pounds) in 154 nondiabetic overweight and obese subjects. 167 In the Diabetes Prevention Program, a randomized controlled trial that enrolled 3,234 overweight and obese individuals at risk of diabetes, a 5% or greater drop in body weight was achieved by 29% of those taking metformin, 63% using lifestyle interventions, and 13% receiving placebo after one year169,170; however, during 15 years of follow-up observation, more metformin users (6.2% compared with 3.7% of lifestyle intervention participants and 2.8% of placebo recipients) maintained their weight loss.171

Metformin is generally well tolerated but can cause diarrhea and digestive upset.172 Extended-release formulations and/or dose titration guided by a clinician may help mitigate these side effects.

Acarbose. Acarbose is an antidiabetic drug that works by inhibiting an important carbohydrate-digesting enzyme, thereby slowing glucose absorption and preventing spikes in blood glucose levels. Acarbose therapy has also been noted to improve lipid levels, blood pressure, blood clotting potential, and blood vessel function.173 Findings from animal studies suggest acarbose may have positive impacts on the gut microbiome that contribute to its metabolic effects.174-176

Treatment with acarbose has been found to reduce body weight in people with type 2 diabetes, and this effect appears to be linked to improved glucose control.163,177,178 In a study in 77 overweight or obese type 2 diabetes patients being treated with metformin and sulfonylureas, the addition of acarbose to the treatment program led to reduced body weight.179 Results from a randomized placebo-controlled trial in 66 nondiabetic obese and overweight subjects indicate acarbose may induce weight loss even in the absence of diabetes.180

People who use acarbose may experience adverse side effects, the most common of which are mild-to-moderate digestive symptoms. These symptoms often diminish with long-term use.181

Emerging Anti-Obesity Drugs

Several drugs used for other indications may hold promise as weight loss interventions, although more research is needed. Examples of these drugs include:

Sodium-glucose co-transport inhibitors. This is a class of drugs being developed for obesity treatment. They work by blocking absorption of glucose in the intestines. Empagliflozin (Jardiance) is an example of a sodium-glucose co-transport inhibitor currently under investigation. 182

Beta-3 adrenergic receptor agonists. This class of drugs increases energy expenditure. So far, one drug in this class has been tested in obese patients: mirabegron (Myrbetriq), at high doses, was found to increase metabolic rate in obese individuals; however, it also triggered rapid heartbeat and other side effects. Researchers are working on developing safer, more selective drugs in this class.182

Monoamine reuptake inhibitors. Drugs in this class raise levels of the neurotransmitters serotonin, dopamine, and noradrenaline. Tesofensine, an experimental drug in the class, was found to suppress appetite and increase thermogenesis; however, it also caused increased heart rate.182 As of late April, 2020, tesofensine was under review by the Mexican FDA as a potential new treatment for obesity; it was not approved in the U.S. at the time.

Bariatric Devices

Several medical devices are available to treat obesity152,155:

  • Gastric balloons partially fill the stomach and reduce the capacity for food. Balloons can be left in the stomach for up to six months.
  • Vagus nerve blockade therapy decreases hunger signals from the stomach. A device is implanted at the junction of the esophagus and stomach, and is connected to a pulse generator under the skin.
  • Gastric emptying system allows the stomach to be emptied 20–30 minutes after eating via an external valve. A study published in 2019 found one such device, branded AspireAssist, to be effective and mostly safe for weight loss over a four-year period. Some adverse events were reported, including some requiring surgical resolution. This device is likely best suited for use in highly motivated patients who will adhere diligently to best usage practices.183
  • Gastric artery embolization is a new technique that involves inserting microparticles into the left gastric artery. By blocking blood supply to part of the stomach, the goal of the procedure is to reduce production of the hunger hormone ghrelin. Although early reports are promising, long-term data from larger groups of people are needed to evaluate the safety and efficacy of gastric artery embolization.155,184

Each of these devices can cause abdominal pain, nausea, and other digestive problems. Gastric emptying can also result in infection and dangerous electrolyte imbalance. In rare cases, gastric balloons can cause gastrointestinal obstruction or perforation.152 In general, bariatric devices are only recommended after dietary, lifestyle, and pharmacologic interventions have been unsuccessful.184

Bariatric Surgeries

Bariatric surgeries are a consideration for people with a BMI ≥40 kg/m2 and those with a BMI ≥35 kg/m2 plus a weight-related condition such as type 2 diabetes. All of these surgical procedures cause changes in digestive function that can interfere with normal nutrient absorption and carry risks of various early and late complications.152

The most common surgery for weight loss is sleeve gastrectomy, in which a line of staples is placed vertically along the mid-stomach and the portion of stomach (about 80%) outside the staple line is removed.152 Newer techniques using endoscopically placed sutures that do not involve removing stomach tissue are now under investigation.155,184 Another common weight loss surgery is Roux-en-Y gastric bypass. In this surgery, a small pouch is created from the stomach and is connected to the mid-intestine (jejunum), bypassing most of the stomach and upper intestine (duodenum and part of the jejunum). Although gastric bypass is associated with the greatest long-term weight loss as well as frequent remission of type 2 diabetes, it is the most complex surgery with the greatest risk of surgical complications.152 The laparoscopic adjustable gastric band procedure is less commonly performed but is the least invasive option. It involves the placement of an adjustable band around the top of the stomach. Gastric bands are associated with the least weight loss and greatest chance of weight regain compared with other bariatric surgeries.152

10 Integrative Interventions for Healthy Weight Loss

Modulating Appetite and Cravings

White kidney bean extract. White kidney bean (Phaseolus vulgaris) contains a compound that inhibits α-amylase, a digestive enzyme required for the conversion of starch to smaller sugars. By inhibiting α-amylase activity, white bean extract can reduce carbohydrate digestion and absorption, and has been reported to lower post-meal spike in blood glucose levels.185,186 A meta-analysis that included 11 clinical trials (including some unpublished data from supplement manufacturers) with a combined total of 573 participants found white bean extract, at a dose of at least 1,200 mg per day for a minimum of four weeks, promoted weight loss in overweight and obese individuals. In addition, three trials examining the effect of white bean extract on fat loss reported significant reductions in fat mass in participants taking the extract.187

Saffron. Extracts of saffron (Crocus sativus) have been studied for a variety of applications, including pain relief, inflammation reduction, and memory and mood enhancement.188 Saffron extract was shown to reduce symptoms of depression in a randomized controlled trial,189 which may explain its potential for reducing the desire to eat. In a study of 60 healthy, mildly overweight women on an unrestricted diet, 176.5 mg saffron stigma extract daily for eight weeks produced an average weight loss of about 2 pounds. Much of this weight reduction was attributed to a reduction in snacking frequency; at the study’s end, individuals on the saffron supplement reported having 5.8 snacks per week (compared with 8.9 snacks per week in the placebo group), a reduction in snacking frequency of 55% from pre-trial levels.190

Thylakoids. Thylakoids are components of plants that participate in plant metabolism. Studies have found that thylakoid ingestion by humans and some animal models helps reduce food cravings and may promote healthy weight loss. Thylakoid ingestion also appears to modulate glucose metabolism and inflammatory signaling.191 Clinical trials have shown supplementation with thylakoid-rich plant preparations leads to greater weight loss than placebo treatment.192 One trial that enrolled 38 overweight women found that thylakoid supplementation decreased subjects’ urge to consume sweets and chocolate. In addition, subjects supplementing with thylakoids in this trial lost significantly more weight (about 3.3. pounds) than those taking placebo. Participants taking thylakoids also had reduced LDL and total cholesterol levels.192,193

Promoting Energy Expenditure

DHEA and 7-Keto DHEA. Dehydroepiandrosterone (DHEA) is an adrenal steroid hormone and a precursor to the sex steroids testosterone and estrogen. Its production by the adrenal gland steadily declines with advancing age. Low DHEA levels have been correlated with higher body weight and percent body fat, and preclinical research suggests supplementation may improve body composition, adipose tissue distribution and function, and metabolism of lipids and carbohydrates.85-87,194 Furthermore, an analysis of four clinical trials found DHEA supplementation increased preservation of bone and muscle mass in aging women.195 One randomized controlled trial that included 61 postmenopausal women with obesity found treatment with 100 mg DHEA for three months resulted in greater weight loss and reductions in waist circumference, blood glucose levels, blood pressure, and other metabolic parameters.196 In a randomized controlled trial in 125 elderly men and women, 50 mg DHEA daily for two years lowered visceral fat mass, improved glucose tolerance, and decreased levels of inflammatory cytokines.197 Another trial found 50 mg DHEA per day for six months led to reduced abdominal fat and improved insulin sensitivity.198

7-Keto DHEA (3-acetyl-7-oxo-dehydroepiandrosterone), a metabolite of DHEA, has been suggested to be a thermogenic agent that could increase energy expenditure.199 In overweight subjects maintained on a calorie-restricted diet, seven days of treatment with 7-Keto DHEA increased REE by 1.4% (equivalent to an extra 115 calories burned per day), whereas subjects taking placebo saw their REE decrease by 3.9%.200 In another randomized controlled trial, overweight volunteers taking 100 mg 7-Keto DHEA twice daily lost significantly more weight and body fat than the placebo group (6.3 pounds vs. 2.2 pounds, respectively, and reductions in body fat of 1.8% vs. 0.57%).201

Inhibiting Absorption of Carbohydrates and Fats

Chromium. Chromium is well known for its ability to improve glucose and lipid metabolism.202 Clinical evidence suggests it may also increase weight loss in overweight and obese individuals. Three meta-analyses of randomized controlled trials have noted small beneficial effects on weight loss when chromium was taken in doses of 200 or 400 mcg daily for a period of 12–16 weeks.203-205 Chromium may be especially helpful for supporting weight loss in overweight and obese individuals with binge eating disorder. In one randomized controlled trial, chromium (as chromium picolinate) reduced binge eating frequency, improved mood, and resulted in more weight loss than placebo in overweight and obese subjects with binge eating disorder. A daily dose of 1,000 mcg was more effective than 600 mcg per day for increasing weight loss and reducing binge eating.206

Irvingia gabonensis. Extracts of the seeds of Irvingia gabonensis, a mango-like West African fruit, may reduce body fat and promote healthy blood lipid and fasting blood glucose levels. Irvingia extracts are thought to inhibit the growth of adipose tissue by down-regulating a protein involved in activating adipose cell growth and proliferation.207 Three clinical trials in subjects with overweight and obesity have reported Irvingia seed extract decreased body fat, body weight, and waist circumference.208-210 One of these trials reported particularly dramatic results. In the trial, Cameroon people who were overweight or obese took 150 mg Irvingia seed extract before meals for 10 weeks; subjects had greater reductions in body fat percentage (-6.3% vs. -1.9%), body weight (-28.2 pounds vs. -1.5 pounds), and waist circumference (-6.37 inches vs. -2.09 inches), as well as reductions in total- and LDL-cholesterol, C-reactive protein, and fasting blood glucose compared with placebo.210,211 These impressive findings need to be confirmed through future research.

Fucoxanthin. Fucoxanthin is a carotenoid pigment from seaweed that has demonstrated several anti-obesity effects. Evidence shows fucoxanthin can inhibit the release and activity of fat-digesting enzymes known as lipases and, in this way, may reduce absorption of dietary fats. Like all carotenoids, fucoxanthin decreases inflammation and enhances free radical scavenging. In addition, fucoxanthin has been found to improve glucose and lipid metabolism, increase the use of fats for energy, and regulate adipose tissue function. Some of its effects appear to be related to modulating the expression of several genes.212

A randomized placebo-controlled trial examined the effects of a supplement with fucoxanthin in 151 premenopausal non-diabetic women with obesity. Women taking a supplement with 300 mg seaweed extract providing 2.4 mg of fucoxanthin, plus 200 mg pomegranate oil, daily for 16 weeks had greater reductions in body weight, body fat, liver fat, waist circumference, triglyceride levels, and levels of C-reactive protein (a marker of inflammation) compared with placebo.213 In a pilot study with two participants, a seaweed plus pomegranate oil supplement providing 3 mg fucoxanthin daily increased brown adipose tissue after three months, suggesting it may increase thermogenesis and energy expenditure.214

Green tea. Green tea contains caffeine and is rich in polyphenolic compounds called catechins, including epigallocatechin gallate (EGCG), which is well known for its powerful antioxidant and anti-inflammatory effects.215,216 It is a common ingredient in weight-loss products and findings from the majority of clinical trials generally support its use for this purpose. In fact, some research suggests green tea catechins and caffeine work synergistically to increase energy expenditure and fat burning.215

Meta-analyses and reviews of randomized controlled trials indicate green tea extract may have a small positive impact on body weight and fat mass in overweight and obese adults.215,217-219 In general, the best results have been reported for those taking green tea extracts providing 100–460 mg EGCG per day for at least 12 weeks.217

Studies have shown that green tea extracts are able to inhibit the activities of several digestive enzymes, potentially reducing the breakdown and absorption of sugars and fats from the intestines.220 Green tea and its polyphenols have also been shown to improve the gut microbiome and increase bacterial production of anti-inflammatory compounds, trigger positive epigenetic mechanisms, stimulate healthy adipose tissue metabolism, and possibly increase thermogenesis.215,221,222 In addition, green tea has been shown to enhance the effects of exercise on fat burning.223

L-arabinose. Sucrose, or common table sugar, is composed of one molecule of glucose and one of fructose. In order to be utilized, it must be broken down by the digestive enzyme sucrase. L-arabinose is an indigestible plant sugar shown to inhibit sucrase, and animal research suggests it may reduce spikes in blood sugar and insulin levels, blood pressure, and fat synthesis that typically follow consumption of high-sugar food or drink.224-226 Pilot studies in healthy adults have shown L-arabinose reduces the impact of sugar consumption on blood glucose and insulin levels.227,228

Modulating Fat Tissue Physiology

Gynostemma. Gynostemma pentaphyllum is an Asian medicinal plant used to lower blood glucose and cholesterol levels, strengthen immunity, and stimulate weight loss. Compounds extracted from gynostemma have been shown to activate a critical enzyme that regulates cellular metabolism and other cell functions: adenosine monophosphate-activated protein kinase (AMPK).237-239 In a randomized placebo-controlled trial that included 80 participants with obesity, 450 mg gynostemma extract per day for 12 weeks resulted in decreased body weight, total abdominal fat area, body fat mass, percent body fat, and BMI.240 Animal research suggests treatment with gynostemma can induce gene expression changes that may result in decreased diet-related adipose tissue growth, weight gain, and metabolic disturbance.241 In a study in mice fed a high-fat diet, treatment with gypenosides (active compounds from gynostemma) had positive effects on the gut microbiome, as well as gene expression, that may have contributed to its ability to increase thermogenesis and adipose tissue browning, reduce weight gain, and exert other metabolic benefits.242

Saccharomyces cerevisiae. Saccharomyces cerevisiae ( S. cerevisiae) is a common yeast used in the production of bread and alcoholic beverages. Yeast hydrolysate is made using enzymes to digest S. cerevisiae. This process yields peptides—short chains of amino acids—that have been found to reduce appetite and decrease abdominal fat accumulation.243-245

A placebo-controlled trial examined the effect of one gram per day of S. cerevisae yeast hydrolysate in obese adults. After six weeks, the S. cerevisae hydrolysate group reduced caloric intake to a significantly greater degree than those receiving placebo. After 10 weeks, the placebo group gained an average of over 1.8 pounds, while the yeast hydrolysate group lost over 5.7 pounds. They also lost significantly more abdominal fat than the placebo group.246 A four-week placebo-controlled trial in 20 obese young women found supplementation with yeast hydrolysate resulted in over 2 pounds more weight loss compared with placebo.247 An additional clinical trial in 30 obese women found that even 0.5 grams of yeast hydrolysate daily was effective; the women taking yeast hydrolysate experienced significant weight, BMI, and body fat reductions after eight weeks. Compared with the control group, the women taking yeast hydrolysate consumed fewer calories, thought less about eating, and had less cravings for sweet foods.248

A study in which subjects underwent brain mapping and completed mood questionnaires found depression and anxiety scores were improved after two weeks of taking yeast hydrolysate.249 Given the evidence for a close association between mood disorders and obesity,250 yeast hydrolysate’s positive impact on weight management may result in part from this neuropsychological effect. Findings from animal research suggest its effects on body weight and body fat may also be related to inhibition of ghrelin, a hormone that stimulates hunger and fat accumulation251,252 and modulation of other appetite-regulating compounds. 253,254 Several animal studies have found yeast hydrolysate administration resulted in improvements in glucose and lipid metabolism,244,255-258 providing evidence for yet another possible beneficial mechanism underlying the weight loss and anti-obesity effects of S. cervisiae yeast hydrolysate.

Guarana. Guarana (Paullinia cupana) is an herbal source of caffeine commonly used for weight loss. In adults with BMI between 29 and 35 kg/m2 participating in an eight-week randomized controlled trial, a combination of guarana and ma huang (Ephedra sinica), providing 240 mg caffeine and 72 mg of stimulating ephedrine alkaloids per day, led to greater weight loss, fat loss, and reductions in triglycerides compared with placebo; however, adverse side effects related to overstimulation were common and resulted in a high rate of withdrawal from the study.259 In animal research, guarana seed powder reduced the negative effects of a high-fat Western-style diet, such as weight gain, lipid level disturbance, fat accumulation, insulin resistance, and adipose tissue dysregulation. It also appeared to increase brown adipose tissue expansion and activity, thereby increasing thermogenesis and energy expenditure.260,261 Changes in gene expression through which guarana may exert benefits have also been identified.261

Sphaeranthus indicus and Garcinia mangostana. Mangosteen (Garcinia mangostana) is a tropical fruit native to Southeast Asia, where it has been used traditionally as a treatment for diabetes. Research shows it has strong antioxidant and anti-inflammatory activities, including in adipose tissue, and improves blood glucose control.262 Another widely used medicinal plant known as East Indian globe thistle (Sphaeranthus indicus) has also demonstrated anti-inflammatory, blood glucose-lowering, and lipid-lowering activities in animal and cell culture models.263 A combination of extracts from mangosteen fruit rind and S. indicus flowers has been studied for its ability to promote weight loss.

In a trial that included 60 participants with obesity, those who received 400 mg S. indicus plus mangosteen twice daily lost an average of approximately 11.2 pounds, 4 inches in waist circumference, and 4 inches in hip circumference after 16 weeks; in contrast, those receiving placebo lost only 2.4 pounds, 1.5 inches in waist circumference, and 2 inches in hip circumference. In addition, mangosteen plus S. indicus was associated with greater reductions in BMI and total cholesterol, LDL-cholesterol, and triglyceride levels.264 Other placebo-controlled trials have similarly noted the efficacy of S. indicus plus mangosteen for increasing weight loss in subjects with overweight and obesity.265-267 Its beneficial effects appear to be due in part to changes in expression of proteins involved in glucose and lipid metabolism in fat cells.265

Conjugated linoleic acid. Conjugated linoleic acid (CLA) is the name given to a specific group of fatty acids derived from linoleic acid. Linoleic acid is an essential omega-6 fatty acid found in many plant foods, while CLA is produced through bacterial fermentation in the digestive tract of ruminant animals such as cows, goats, and sheep. Thus, some major food sources of CLA are beef and dairy products. CLA can also be synthetically produced from oils high in linoleic acid, such as soy, corn, safflower, and sunflower oils.268,269

CLA appears to promote fat breakdown, inhibit fatty acid production and storage, and reduce inflammatory signaling in fat tissue. It has also been shown to work at the epigenetic level, inducing fat browning by altering fat cells’ production of enzymes involved in fat and glucose metabolism.269,270 Although evidence from clinical trials is mixed, multiple randomized controlled trials have reported reductions in fat mass and body weight in overweight and obese subjects after taking 3–6 grams of CLA per day over time periods ranging from 12 weeks to two years.268,269

Additional Support

Lipoic acid. Alpha [α]-lipoic acid (ALA) is an organosulfur antioxidant produced by plants, animals, and humans. ALA is primarily found in the mitochondria of cells, where it facilitates various enzymatic reactions necessary for cell function. Two enantiomers (ie, mirror-image molecular structures) of ALA exist: “R” and “S.” The R form of ALA is the primary natural form found in foods, such as meat and vegetables, and produced in humans. Therefore, the R-isomer of ALA is believed to be the form that exerts most of the biologic effects of ALA. In contrast, the S-isomer is not generally found in nature and is instead synthesized through chemical processes.320 In some supplements, ALA may be provided in a mixture of R and S forms, called a racemic mixture. Other supplements provide 100% R-ALA, which could potentially maximize the weight loss benefits of ALA supplementation.320,321

ALA—and particularly R-ALA—has been shown to be effective for improving weight loss. In a 2020 randomized trial, 24 weeks of supplementation with R-ALA in 81 overweight adults with a BMI of 25 kg/m2 or higher and elevated plasma triglyceride levels resulted in significantly more weight loss than placebo, with a relative reduction in BMI of 0.8 kg/m2. The effect was more pronounced in obese participants with BMI of 35 kg/m2 or higher. These participants had 4.8% more weight loss and 8.6% more body fat loss than those treated with placebo.321 Racemic mixtures of R- and S-ALA have also shown benefit for weight loss; however, these changes may not be as large as those seen in the clinical trial evaluating R-ALA alone, with weight loss relative to placebo reported at 2.1% in one randomized controlled trial.322-324 Meta-analyses of randomized controlled trials revealed that ALA supplementation results in weight loss of 0.69 to 1.27 kg (1.5 to 2.8 lb.) and BMI reductions of 0.38 to 0.43 kg/m2.325,326

For people treated with medications that may cause weight gain, such as antipsychotics used to treat schizophrenia, ALA has been shown to have a protective effect. In a study of 22 overweight, clinically stable patients with schizophrenia, 600 to 1,800 mg ALA per day for 12 weeks resulted in significantly greater levels of weight loss and visceral fat levels relative to placebo.327 In an open-label study, participants using antipsychotics who were treated with 1,200 mg ALA lost an average of 2.2 kg (4.8 lb.).328

Although the mechanism of action by which R-ALA exerts its weight loss effects is unclear, there is some evidence that these effects are linked to antioxidant effects and metabolic changes. In a randomized controlled trial, treatment with R-ALA increased the expression of the antioxidant gene HMOX1 22% more than placebo.321 ALA has also been shown to substantially decrease levels of several inflammatory markers, including interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-ɑ).329 Many of these inflammatory markers are produced by fat tissue and contribute to the chronic inflammatory state that has been associated with obesity.329,330 ALA, alone and in combination with other ingredients, has also been shown to exert favorable metabolic changes, including reductions in glucose and insulin levels.331-333 ALA may also affect cardiovascular risk factors, with one study showing that ALA treatment improved vascular tone in obese or overweight children and adolescents.333

Coffee. Both green and roasted coffee beans contain active constituents that may help promote healthy weight loss, including caffeine, a family of polyphenols called chlorogenic acids, and prebiotic compounds called mannooligosaccharides.271,272 Coffee drinking has been linked to decreased risk of an array of chronic health problems including heart disease, type 2 diabetes, and obesity, as well as lower risk of death from any cause, in multiple observational studies.271 A review and meta-analysis of clinical trials examining the health effects of coffee determined three to four cups of coffee per day is associated with the greatest overall health benefit.271 A recent study found coffee consumption was only correlated with lower body weight, BMI, and body fat in subjects with a particular variant of a gene involved in adipose tissue thermogenesis (heat generation).273

Green coffee beans, which are higher in chlorogenic acids than roasted beans, have been investigated for their ability to increase weight loss. A meta-analysis of 16 randomized controlled trials found supplementing with green coffee extract significantly reduced BMI, and had a greater weight-reducing effect in participants with a BMI indicating overweight or obesity (≥25 kg/m2).274 A randomized controlled trial in 52 normal-weight participants found drinking a beverage made from green and roasted coffee three times daily for eight weeks led to reductions in percent body fat, blood pressure, insulin resistance, blood glucose levels, and triglyceride levels, suggesting this combination may help prevent or treat metabolic syndrome.275

Whey protein. Whey protein supports the growth of muscle tissue, improves satiety signaling, and promotes thermogenesis.276 Clinical trials indicate whey protein can help preserve lean body mass during body weight and fat mass reduction through diet and exercise in people with overweight and obesity.277,278 A randomized controlled trial in women who regained weight after gastric bypass surgery found supplementing with whey protein (0.5 grams/kg of ideal body weight) for 16 weeks promoted greater body weight and fat mass reductions with no loss of lean body mass. 279 A meta-analysis of nine controlled trials determined whey protein not only enhanced weight and fat loss, it also decreased cardiovascular risk by improving lipid levels, blood glucose levels, and blood pressure.280 Some studies indicate whey protein may attenuate the increase in appetite that usually accompanies calorie reduction and weight loss.278

Probiotics. Probiotics are microorganisms used to modulate the gut microbiome and promote health. Numerous clinical trials have investigated the potential of probiotic supplements to promote weight loss and prevent and treat metabolic disorders. Meta-analyses and reviews of randomized controlled trials show probiotic supplements containing various Lactobacillus and Bifidobacterium strains can help reduce body weight, BMI, waist circumference, fat mass, and percent body fat.281-285 In addition, probiotic use is associated with improvements in cholesterol levels and markers of glucose metabolism.281,284 One analysis determined the most robust effects have been associated with supplements containing two or more strains at modest doses (below 10 billion colony forming units [CFUs] per day).281

An abundance of the gut bacterium Akkermansia muciniphila has been correlated with metabolic health, and low amounts are found in people with obesity. A heat-killed form of A. muciniphila has shown promising effects in pilot trials in obese mice and humans, suggesting its potential as a therapeutic aid in weight loss.286,287

Fish oil. Omega-3 fatty acids from fish (mainly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) have anti-inflammatory effects, and evidence suggests they may promote healthy metabolism by reducing insulin resistance and inflammatory signaling by adipose tissue.288 Fish oil and omega-3 fatty acids may also increase satiety, improve regulation of leptin and adiponectin, and trigger epigenetic mechanisms associated with reduced growth of adipose tissue.289,290 In a placebo controlled trial that included 65 overweight and obese participants with depression, taking 1,080 mg EPA and 720 mg DHA daily for 12 weeks decreased depression symptoms and enhanced weight loss.291 A meta-analysis of randomized controlled trials determined omega-3 fatty acids from fish may induce reductions in waist circumference and triglyceride levels, indicating improved metabolic health, in individuals with overweight and obesity.292

Capsaicin. Capsaicin is an active compound found in chili peppers ( Capsicum annuum) and is responsible for their hot taste. Capsaicin activates the sympathetic (fight-or-flight) part of the nervous system, reducing appetite while increasing thermogenesis, energy expenditure, and fat tissue breakdown (lipolysis).293,294 Through these effects, capsaicin may counter the body’s adaptive response to reduced calorie intake and enhance weight loss. Furthermore, it is thought to contribute to healthy metabolism by promoting normal sleep patterns through its analgesic action.294

A meta-analysis of eight randomized controlled trials with a combined total of 191 subjects found daily intake of at least 2 mg of capsaicin reduced appetite.295 Another review noted capsaicin and related chili pepper compounds can reduce appetite, calorie consumption, and abdominal adipose tissue mass.296 In a placebo-controlled trial with 50 overweight female participants, those who received 50 mg capsaicin, along with 250 mg green tea and 100 mg ginger, twice daily for eight weeks lost significantly more weight than those who received placebo.297 In a study investigating the short-term effects of capsaicin, a single 2 mg dose of capsaicin increased REE after a meal in young adults with obesity. 298

Tryptophan and 5-HTP. Tryptophan is an essential amino acid and a precursor to serotonin, a neurotransmitter produced by gut microbes, intestinal cells, and brain cells.299 Serotonin is involved in gastrointestinal function as well as mood, appetite, and energy balance regulation. In the brain, higher serotonin levels signal satiety and lower levels signal the desire to eat.300 Calorie-restricted diets, while successful at reducing weight, have been shown to reduce circulating tryptophan levels by 15‒21%. This may lead to reduced serotonin synthesis, worsening of mood, increased carbohydrate cravings, and an increased chance of weight regain.301 In a study of 10 healthy, young, normal-weight men, 2- and 3-gram doses of tryptophan reduced energy intake compared with placebo when taken before a buffet-style meal.302 In a study that included 10 obese subjects, 1, 2, or 3 grams of tryptophan, taken one hour before a meal, reduced calorie consumption. Its appetite-reducing effect increased as the dose of tryptophan increased. 303

5-hydroxytryptophan (5-HTP) is a breakdown product made from tryptophan along the pathway that results in serotonin. Several clinical trials have reported beneficial effects of 5-HTP on weight loss.304-306 In one randomized controlled trial that included 25 overweight patients with type 2 diabetes, 750 mg 5-HTP daily for two weeks reduced calorie consumption and body weight compared with placebo.305

Pine nut oil. Pine nut oil, which contains a constituent called pinolenic acid, has been shown to reduce food intake. When doses of pine nut oil ranging from 2 to 6 grams were given to overweight female subjects prior to a buffet-style meal, food consumption was reduced up to 9% compared with placebo. The researchers suggested this reduced food intake was attributable to pine nut oil’s satiating effects, which may be mediated via modulation of cholecystokinin (CCK) and other appetite-suppressing compounds.307 In a placebo-controlled crossover trial, 18 overweight women were given 3 grams of a pine nut oil extract or placebo before breakfast and were monitored for four hours. The treatment group reported lower appetite and had higher levels of hormones that suppress appetite during the four hours following pine nut oil compared with placebo.308 Pine nut oil has been found to prevent diet-induced weight gain, fat mass gain, and abdominal fat accumulation in animals studies.309,310 Some evidence suggests pine nut oil increases thermogenesis and improves metabolic activity in adipose tissue.311

L-carnitine. L-carnitine, a non-essential amino acid made in the body and obtained in the diet from meat and dairy foods, plays a key role in moving fatty acids across mitochondrial membranes and thereby facilitating fat metabolism.312 A meta-analysis of 43 controlled trials with a combined total of 2,703 participants found supplementing with at least 2 grams per day of L-carnitine reduced body weight, body fat mass, and BMI in those with overweight and obesity.313 Because L-carnitine reduces oxidative stress, supports healthy mitochondrial function, and exhibits cell-protective effects, it may also help prevent some of the many health problems associated with overweight and obesity.312

Coleus forskohlii. Coleus forskohlii is a medicinal plant from the Ayurvedic tradition. Its historical uses include treatment of high blood pressure, heart failure, eczema, digestive colic, respiratory ailments, painful urination, insomnia, and seizures.314 Preclinical research shows forskolin, an active compound from Coleus, reduces inflammatory signaling by fat cells.315

In preliminary research, six overweight women treated with 250 mg Coleus forskohlii extract, standardized to contain 10% forskolin, twice daily for eight weeks lost an average of 10 pounds of body weight and 8% of body fat.316 In a placebo-controlled trial in 23 overweight women, those receiving 250 mg Coleus forskohlii standardized extract twice daily for 12 weeks lost 0.6 kg of body weight while those receiving placebo gained 1.3 kg; although the difference was not statistically significant, it did indicate a possible benefit of Coleus in slowing weight gain.317 Another 12-week trial compared the effects of 250 mg Coleus forskohlii standardized extract twice daily to placebo in 30 adults with overweight or obesity eating a reduced-calorie diet. Coleus did not differ from placebo in its effect on body weight, but was associated with greater improvement in insulin levels and insulin resistance, suggesting it may have a role in improving metabolic health.318

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.

  1. Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. International journal of molecular sciences. 2019;20(9).
  2. Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. Journal of the American College of Cardiology. 2018;71(17):1857-1865.
  3. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17.
  4. De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? Journal of translational medicine. 2019;17(1):169.
  5. Uranga RM, Keller JN. The Complex Interactions Between Obesity, Metabolism and the Brain. Front Neurosci. 2019;13:513.
  6. Niccolai E, Boem F, Russo E, Amedei A. The Gut(-)Brain Axis in the Neuropsychological Disease Model of Obesity: A Classical Movie Revised by the Emerging Director "Microbiome". Nutrients. 2019;11(1).
  7. Collaboration NRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377-1396.
  8. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS data brief. 2017(288):1-8.
  9. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. New England Journal of Medicine. 2019;381(25):2440-2450.
  10. Willoughby D, Hewlings S, Kalman D. Body Composition Changes in Weight Loss: Strategies and Supplementation for Maintaining Lean Body Mass, a Brief Review. Nutrients. 2018;10(12):1876.
  11. Soeliman FA, Azadbakht L. Weight loss maintenance: A review on dietary related strategies. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2014;19(3):268-275.
  12. Yannakoulia M, Poulimeneas D, Mamalaki E, Anastasiou CA. Dietary modifications for weight loss and weight loss maintenance. Metabolism: clinical and experimental. 2019;92:153-162.
  13. Pi-Sunyer X. Changes in body composition and metabolic disease risk. European journal of clinical nutrition. 2019;73(2):231-235.
  14. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current obesity reports. 2017;6(2):187-194.
  15. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. Journal of the National Cancer Institute. 2015;107(2).
  16. Hall KD, Guo J. Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition. Gastroenterology. 2017;152(7):1718-1727.e1713.
  17. Yoo S. Dynamic Energy Balance and Obesity Prevention. J Obes Metab Syndr. 2018;27(4):203-212.
  18. Fonseca DC, Sala P, de Azevedo Muner Ferreira B, et al. Body weight control and energy expenditure. Clinical Nutrition Experimental. 2018;20:55-59.
  19. Cronise RJ, Sinclair DA, Bremer AA. Oxidative Priority, Meal Frequency, and the Energy Economy of Food and Activity: Implications for Longevity, Obesity, and Cardiometabolic Disease. Metabolic syndrome and related disorders. 2017;15(1):6-17.
  20. Anton SD, Moehl K, Donahoo WT, et al. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity (Silver Spring). 2018;26(2):254-268.
  21. Hafidi ME, Buelna-Chontal M, Sanchez-Munoz F, Carbo R. Adipogenesis: A Necessary but Harmful Strategy. International journal of molecular sciences. 2019;20(15).
  22. Müller MJ, Enderle J, Bosy-Westphal A. Changes in Energy Expenditure with Weight Gain and Weight Loss in Humans. Current obesity reports. 2016;5(4):413-423.
  23. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978-3989.
  24. Beh S. Is metabolically healthy obesity a useful concept? Diabet Med. 2019;36(5):539-545.
  25. Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. Medicine. 2017;96(47):e8838.
  26. Ortega FB, Cadenas-Sanchez C, Migueles JH, et al. Role of Physical Activity and Fitness in the Characterization and Prognosis of the Metabolically Healthy Obesity Phenotype: A Systematic Review and Meta-analysis. Progress in cardiovascular diseases. 2018;61(2):190-205.
  27. Loos RJF, Kilpelainen TO. Genes that make you fat, but keep you healthy. J Intern Med. 2018;284(5):450-463.
  28. Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism: clinical and experimental. 2019;92:51-60.
  29. Thaker VV. GENETIC AND EPIGENETIC CAUSES OF OBESITY. Adolesc Med State Art Rev. 2017;28(2):379-405.
  30. Loh M, Zhou L, Ng HK, Chambers JC. Epigenetic disturbances in obesity and diabetes: Epidemiological and functional insights. Molecular metabolism. 2019;27s:S33-s41.
  31. Veenendaal MV, Painter RC, de Rooij SR, et al. Transgenerational effects of prenatal exposure to the 1944-45 Dutch famine. BJOG : an international journal of obstetrics and gynaecology. 2013;120(5):548-553.
  32. Portha B, Grandjean V, Movassat J. Mother or Father: Who Is in the Front Line? Mechanisms Underlying the Non-Genomic Transmission of Obesity/Diabetes via the Maternal or the Paternal Line. Nutrients. 2019;11(2).
  33. Wroblewski A, Strycharz J, Swiderska E, et al. Molecular Insight into the Interaction between Epigenetics and Leptin in Metabolic Disorders. Nutrients. 2019;11(8).
  34. van Dijk SJ, Tellam RL, Morrison JL, Muhlhausler BS, Molloy PL. Recent developments on the role of epigenetics in obesity and metabolic disease. Clin Epigenetics. 2015;7:66.
  35. Ling C, Ronn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell metabolism. 2019;29(5):1028-1044.
  36. Hanjani NA, Vafa M. Protein Restriction, Epigenetic Diet, Intermittent Fasting as New Approaches for Preventing Age-associated Diseases. International journal of preventive medicine. 2018;9:58.
  37. Russo GL, Vastolo V, Ciccarelli M, Albano L, Macchia PE, Ungaro P. Dietary polyphenols and chromatin remodeling. Crit Rev Food Sci Nutr. 2017;57(12):2589-2599.
  38. Zhu Q, Glazier BJ, Hinkel BC, et al. Neuroendocrine Regulation of Energy Metabolism Involving Different Types of Adipose Tissues. International journal of molecular sciences. 2019;20(11).
  39. Engin AB. What Is Lipotoxicity? Adv Exp Med Biol. 2017;960:197-220.
  40. Atawia RT, Bunch KL, Toque HA, Caldwell RB, Caldwell RW. Mechanisms of obesity-induced metabolic and vascular dysfunctions. Frontiers in bioscience (Landmark edition). 2019;24:890-934.
  41. Srivastava S, Veech RL. Brown and Brite: The Fat Soldiers in the Anti-obesity Fight. Front Physiol. 2019;10:38.
  42. Herz CT, Kiefer FW. Adipose tissue browning in mice and humans. The Journal of endocrinology. 2019;241(3):R97-r109.
  43. Kaisanlahti A, Glumoff T. Browning of white fat: agents and implications for beige adipose tissue to type 2 diabetes. J Physiol Biochem. 2019;75(1):1-10.
  44. Villarroya F, Cereijo R, Gavalda-Navarro A, Villarroya J, Giralt M. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. J Intern Med. 2018;284(5):492-504.
  45. Arhire LI, Mihalache L, Covasa M. Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome. Frontiers in endocrinology. 2019;10:524.
  46. Fruhbeck G, Catalan V, Rodriguez A, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7(1):6619.
  47. Mancuso P, Bouchard B. The Impact of Aging on Adipose Function and Adipokine Synthesis. Frontiers in endocrinology. 2019;10:137.
  48. Parida S, Siddharth S, Sharma D. Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease. International journal of molecular sciences. 2019;20(10).
  49. Timper K, Bruning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Disease models & mechanisms. 2017;10(6):679-689.
  50. Miller GD. Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity. American journal of lifestyle medicine. 2019;13(6):586-601.
  51. Serrenho D, Santos SD, Carvalho AL. The Role of Ghrelin in Regulating Synaptic Function and Plasticity of Feeding-Associated Circuits. Frontiers in cellular neuroscience. 2019;13:205.
  52. Poher AL, Tschop MH, Muller TD. Ghrelin regulation of glucose metabolism. Peptides. 2018;100:236-242.
  53. Makris MC, Alexandrou A, Papatsoutsos EG, et al. Ghrelin and Obesity: Identifying Gaps and Dispelling Myths. A Reappraisal. In Vivo. 2017;31(6):1047-1050.
  54. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;23(7):804-814.
  55. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1-4.
  56. Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Seminars in immunopathology. 2018;40(2):215-224.
  57. Fabiani R, Naldini G, Chiavarini M. Dietary Patterns and Metabolic Syndrome in Adult Subjects: A Systematic Review and Meta-Analysis. Nutrients. 2019;11(9).
  58. Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleinewietfeld M. Role of "Western diet" in inflammatory autoimmune diseases. Current allergy and asthma reports. 2014;14(1):404.
  59. Mendrick DL, Diehl AM, Topor LS, et al. Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic. Toxicological Sciences. 2017;162(1):36-42.
  60. Turner A, Veysey M, Keely S, Scarlett C, Lucock M, Beckett EL. Interactions between Bitter Taste, Diet and Dysbiosis: Consequences for Appetite and Obesity. Nutrients. 2018;10(10).
  61. Lazar V, Ditu LM, Pircalabioru GG, et al. Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity. Frontiers in nutrition. 2019;6:21.
  62. Covasa M, Stephens RW, Toderean R, Cobuz C. Intestinal Sensing by Gut Microbiota: Targeting Gut Peptides. Frontiers in endocrinology. 2019;10:82.
  63. Stols-Goncalves D, Tristao LS, Henneman P, Nieuwdorp M. Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-alcoholic Fatty Liver Disease. Current diabetes reports. 2019;19(6):31.
  64. Parkar SG, Kalsbeek A, Cheeseman JF. Potential Role for the Gut Microbiota in Modulating Host Circadian Rhythms and Metabolic Health. Microorganisms. 2019;7(2).
  65. Gerard C, Vidal H. Impact of Gut Microbiota on Host Glycemic Control. Frontiers in endocrinology. 2019;10:29.
  66. Mitev K, Taleski V. Association between the Gut Microbiota and Obesity. Open Access Maced J Med Sci. 2019;7(12):2050-2056.
  67. Million M, Lagier JC, Yahav D, Paul M. Gut bacterial microbiota and obesity. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2013;19(4):305-313.
  68. Zimmet P, Alberti K, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more! J Intern Med. 2019;286(2):181-191.
  69. Bae SA, Fang MZ, Rustgi V, Zarbl H, Androulakis IP. At the Interface of Lifestyle, Behavior, and Circadian Rhythms: Metabolic Implications. Frontiers in nutrition. 2019;6:132.
  70. Serin Y, Acar Tek N. Effect of Circadian Rhythm on Metabolic Processes and the Regulation of Energy Balance. Ann Nutr Metab. 2019;74(4):322-330.
  71. Poggiogalle E, Jamshed H, Peterson CM. Circadian regulation of glucose, lipid, and energy metabolism in humans. Metabolism: clinical and experimental. 2018;84:11-27.
  72. Paschos GK, FitzGerald GA. Circadian Clocks and Metabolism: Implications for Microbiome and Aging. Trends Genet. 2017;33(10):760-769.
  73. Joshi SR. Thyro-weight: Unlocking the Link between Thyroid Disorders and Weight. J Assoc Physicians India. 2018;66(3):75-78.
  74. Santini F, Marzullo P, Rotondi M, et al. Mechanisms in endocrinology: the crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. European journal of endocrinology / European Federation of Endocrine Societies. 2014;171(4):R137-152.
  75. Yavuz S, Salgado Nunez Del Prado S, Celi FS. Thyroid Hormone Action and Energy Expenditure. Journal of the Endocrine Society. 2019;3(7):1345-1356.
  76. Vaitkus JA, Farrar JS, Celi FS. Thyroid Hormone Mediated Modulation of Energy Expenditure. International journal of molecular sciences. 2015;16(7):16158-16175.
  77. Lankhaar JA, de Vries WR, Jansen JA, Zelissen PM, Backx FJ. Impact of overt and subclinical hypothyroidism on exercise tolerance: a systematic review. Res Q Exerc Sport. 2014;85(3):365-389.
  78. Karvonen-Gutierrez C, Kim C. Association of Mid-Life Changes in Body Size, Body Composition and Obesity Status with the Menopausal Transition. Healthcare (Basel, Switzerland). 2016;4(3).
  79. Gonzalez-Garcia I, Tena-Sempere M, Lopez M. Estradiol Regulation of Brown Adipose Tissue Thermogenesis. Adv Exp Med Biol. 2017;1043:315-335.
  80. Fowler N, Vo PT, Sisk CL, Klump KL. Stress as a potential moderator of ovarian hormone influences on binge eating in women. F1000Research. 2019;8.
  81. Roney JR, Simmons ZL. Ovarian hormone fluctuations predict within-cycle shifts in women's food intake. Hormones and behavior. 2017;90:8-14.
  82. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. Human reproduction update. 2017;23(3):300-321.
  83. Tchernof A, Brochu D, Maltais-Payette I, et al. Androgens and the Regulation of Adiposity and Body Fat Distribution in Humans. Compr Physiol. 2018;8(4):1253-1290.
  84. Khera M. Male hormones and men's quality of life. Current opinion in urology. 2016;26(2):152-157.
  85. Vihma V, Heinonen S, Naukkarinen J, et al. Increased body fat mass and androgen metabolism - A twin study in healthy young women. Steroids. 2018;140:24-31.
  86. Aoki K, Terauchi Y. Effect of Dehydroepiandrosterone (DHEA) on Diabetes Mellitus and Obesity. Vitamins and hormones. 2018;108:355-365.
  87. Karbowska J, Kochan Z. Effects of DHEA on metabolic and endocrine functions of adipose tissue. Hormone molecular biology and clinical investigation. 2013;14(2):65-74.
  88. Tumin R, Anderson SE. Television, Home-Cooked Meals, and Family Meal Frequency: Associations with Adult Obesity. Journal of the Academy of Nutrition and Dietetics. 2017;117(6):937-945.
  89. Martin-Biggers J, Spaccarotella K, Berhaupt-Glickstein A, Hongu N, Worobey J, Byrd-Bredbenner C. Come and get it! A discussion of family mealtime literature and factors affecting obesity risk. Adv Nutr. 2014;5(3):235-247.
  90. MacLean PS, Blundell JE, Mennella JA, Batterham RL. Biological control of appetite: A daunting complexity. Obesity (Silver Spring). 2017;25 Suppl 1:S8-s16.
  91. Dorling J, Broom DR, Burns SF, et al. Acute and Chronic Effects of Exercise on Appetite, Energy Intake, and Appetite-Related Hormones: The Modulating Effect of Adiposity, Sex, and Habitual Physical Activity. Nutrients. 2018;10(9).
  92. Ans AH, Anjum I, Satija V, et al. Neurohormonal Regulation of Appetite and its Relationship with Stress: A Mini Literature Review. Cureus. 2018;10(7):e3032.
  93. Berthoud HR, Munzberg H, Morrison CD. Blaming the Brain for Obesity: Integration of Hedonic and Homeostatic Mechanisms. Gastroenterology. 2017;152(7):1728-1738.
  94. Yoo EG. Waist-to-height ratio as a screening tool for obesity and cardiometabolic risk. Korean journal of pediatrics. 2016;59(11):425-431.
  95. CDC. Centers for Disease Control and Prevention. Defining Adult Overweight and Obesity. Available at https://www.cdc.gov/obesity/adult/defining.html. Last updated 04/11/2017. Accessed 11/08/2019. 2017.
  96. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest. 2015;125(5):1790-1792.
  97. Correa MM, Thume E, De Oliveira ER, Tomasi E. Performance of the waist-to-height ratio in identifying obesity and predicting non-communicable diseases in the elderly population: A systematic literature review. Arch Gerontol Geriatr. 2016;65:174-182.
  98. Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes, metabolic syndrome and obesity : targets and therapy. 2013;6:403-419.
  99. Millar SR, Perry IJ, Phillips CM. Assessing cardiometabolic risk in middle-aged adults using body mass index and waist-height ratio: are two indices better than one? A cross-sectional study. Diabetol Metab Syndr. 2015;7:73.
  100. Lam BC, Koh GC, Chen C, Wong MT, Fallows SJ. Comparison of Body Mass Index (BMI), Body Adiposity Index (BAI), Waist Circumference (WC), Waist-To-Hip Ratio (WHR) and Waist-To-Height Ratio (WHtR) as predictors of cardiovascular disease risk factors in an adult population in Singapore. PLoS One. 2015;10(4):e0122985.
  101. Smethers AD, Rolls BJ. Dietary Management of Obesity: Cornerstones of Healthy Eating Patterns. The Medical clinics of North America. 2018;102(1):107-124.
  102. Koliaki C, Spinos T, Spinou M, Brinia Mu E, Mitsopoulou D, Katsilambros N. Defining the Optimal Dietary Approach for Safe, Effective and Sustainable Weight Loss in Overweight and Obese Adults. Healthcare (Basel, Switzerland). 2018;6(3).
  103. Joshi S, Mohan V. Pros & cons of some popular extreme weight-loss diets. The Indian journal of medical research. 2018;148(5):642-647.
  104. Hayes J, Benson G. What the Latest Evidence Tells Us About Fat and Cardiovascular Health. Diabetes Spectrum. 2016;29(3):171-175.
  105. Brandhorst S, Longo VD. Dietary Restrictions and Nutrition in the Prevention and Treatment of Cardiovascular Disease. Circulation Research. 2019;124(6):952-965.
  106. Locke A, Schneiderhan J, Zick SM. Diets for Health: Goals and Guidelines. American family physician. 2018;97(11):721-728.
  107. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ (Clinical research ed). 2017;359:j4849.
  108. Lu M, Wan Y, Yang B, Huggins CE, Li D. Effects of low-fat compared with high-fat diet on cardiometabolic indicators in people with overweight and obesity without overt metabolic disturbance: a systematic review and meta-analysis of randomised controlled trials. The British journal of nutrition. 2018;119(1):96-108.
  109. Hamdy O, Tasabehji MW, Elseaidy T, Tomah S, Ashrafzadeh S, Mottalib A. Fat Versus Carbohydrate-Based Energy-Restricted Diets for Weight Loss in Patients With Type 2 Diabetes. Current diabetes reports. 2018;18(12):128.
  110. Brouns F. Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet recommendable? European journal of nutrition. 2018;57(4):1301-1312.
  111. Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. 2018;3(9):e419-e428.
  112. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. The Medical clinics of North America. 2018;102(1):183-197.
  113. van Baak MA, Mariman ECM. Dietary Strategies for Weight Loss Maintenance. Nutrients. 2019;11(8).
  114. Ojha U. Protein-induced satiation and the calcium-sensing receptor. Diabetes, metabolic syndrome and obesity : targets and therapy. 2018;11:45-51.
  115. Liauchonak I, Qorri B, Dawoud F, Riat Y, Szewczuk MR. Non-Nutritive Sweeteners and Their Implications on the Development of Metabolic Syndrome. Nutrients. 2019;11(3).
  116. Daher MI, Matta JM, Abdel Nour AM. Non-nutritive sweeteners and type 2 diabetes: Should we ring the bell? Diabetes Res Clin Pract. 2019;155:107786.
  117. Romo-Romo A, Aguilar-Salinas CA, Gomez-Diaz RA, et al. Non-Nutritive Sweeteners: Evidence on their Association with Metabolic Diseases and Potential Effects on Glucose Metabolism and Appetite. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2017;69(3):129-138.
  118. Pearlman M, Obert J, Casey L. The Association Between Artificial Sweeteners and Obesity. Current gastroenterology reports. 2017;19(12):64.
  119. Rother KI, Conway EM, Sylvetsky AC. How Non-nutritive Sweeteners Influence Hormones and Health. Trends in endocrinology and metabolism: TEM. 2018;29(7):455-467.
  120. Suez J, Korem T, Zilberman-Schapira G, Segal E, Elinav E. Non-caloric artificial sweeteners and the microbiome: findings and challenges. Gut Microbes. 2015;6(2):149-155.
  121. Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Mediterranean diet and weight loss: meta-analysis of randomized controlled trials. Metabolic syndrome and related disorders. 2011;9(1):1-12.
  122. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic Review of the Mediterranean Diet for Long-Term Weight Loss. Am J Med. 2016;129(4):407-415.e404.
  123. Castro-Barquero S, Lamuela-Raventos RM, Domenech M, Estruch R. Relationship between Mediterranean Dietary Polyphenol Intake and Obesity. Nutrients. 2018;10(10).
  124. Bailey MA, Holscher HD. Microbiome-Mediated Effects of the Mediterranean Diet on Inflammation. Adv Nutr. 2018;9(3):193-206.
  125. Turner-McGrievy G, Mandes T, Crimarco A. A plant-based diet for overweight and obesity prevention and treatment. Journal of geriatric cardiology : JGC. 2017;14(5):369-374.
  126. Orlich MJ, Fraser GE. Vegetarian diets in the Adventist Health Study 2: a review of initial published findings. Am J Clin Nutr. 2014;100 Suppl 1:353s-358s.
  127. Kahleova H, Levin S, Barnard N. Cardio-Metabolic Benefits of Plant-Based Diets. Nutrients. 2017;9(8).
  128. Huang RY, Huang CC, Hu FB, Chavarro JE. Vegetarian Diets and Weight Reduction: a Meta-Analysis of Randomized Controlled Trials. J Gen Intern Med. 2016;31(1):109-116.
  129. Karlsen MC, Rogers G, Miki A, et al. Theoretical Food and Nutrient Composition of Whole-Food Plant-Based and Vegan Diets Compared to Current Dietary Recommendations. Nutrients. 2019;11(3).
  130. Zubrzycki A, Cierpka-Kmiec K, Kmiec Z, Wronska A. The role of low-calorie diets and intermittent fasting in the treatment of obesity and type-2 diabetes. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2018;69(5).
  131. Rynders CA, Thomas EA, Zaman A, Pan Z, Catenacci VA, Melanson EL. Effectiveness of Intermittent Fasting and Time-Restricted Feeding Compared to Continuous Energy Restriction for Weight Loss. Nutrients. 2019;11(10).
  132. Dreher ML. Whole Fruits and Fruit Fiber Emerging Health Effects. Nutrients. 2018;10(12).
  133. Thomas JG, Bond DS, Phelan S, Hill JO, Wing RR. Weight-loss maintenance for 10 years in the National Weight Control Registry. Am J Prev Med. 2014;46(1):17-23.
  134. Melby CL, Paris HL, Foright RM, Peth J. Attenuating the Biologic Drive for Weight Regain Following Weight Loss: Must What Goes Down Always Go Back Up? Nutrients. 2017;9(5).
  135. Jakicic JM, Rogers RJ, Davis KK, Collins KA. Role of Physical Activity and Exercise in Treating Patients with Overweight and Obesity. Clinical chemistry. 2018;64(1):99-107.
  136. Kim BY, Choi DH, Jung CH, Kang SK, Mok JO, Kim CH. Obesity and Physical Activity. J Obes Metab Syndr. 2017;26(1):15-22.
  137. Fletcher GF, Landolfo C, Niebauer J, Ozemek C, Arena R, Lavie CJ. Promoting Physical Activity and Exercise: JACC Health Promotion Series. Journal of the American College of Cardiology. 2018;72(14):1622-1639.
  138. Ekelund U, Ward HA, Norat T, et al. Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC). Am J Clin Nutr. 2015;101(3):613-621.
  139. Maillard F, Pereira B, Boisseau N. Effect of High-Intensity Interval Training on Total, Abdominal and Visceral Fat Mass: A Meta-Analysis. Sports medicine (Auckland, NZ). 2018;48(2):269-288.
  140. Cassidy S, Thoma C, Houghton D, Trenell MI. High-intensity interval training: a review of its impact on glucose control and cardiometabolic health. Diabetologia. 2017;60(1):7-23.
  141. Turk Y, Theel W, Kasteleyn MJ, et al. High intensity training in obesity: a Meta-analysis. Obesity science & practice. 2017;3(3):258-271.
  142. Brewer JA, Ruf A, Beccia AL, et al. Can Mindfulness Address Maladaptive Eating Behaviors? Why Traditional Diet Plans Fail and How New Mechanistic Insights May Lead to Novel Interventions. Frontiers in psychology. 2018;9:1418.
  143. Eichen DM, Matheson BE, Appleton-Knapp SL, Boutelle KN. Neurocognitive Treatments for Eating Disorders and Obesity. Curr Psychiatry Rep. 2017;19(9):62.
  144. Chen J, Papies EK, Barsalou LW. A core eating network and its modulations underlie diverse eating phenomena. Brain Cogn. 2016;110:20-42.
  145. Fulwiler C, Brewer JA, Sinnott S, Loucks EB. Mindfulness-Based Interventions for Weight Loss and CVD Risk Management. Curr Cardiovasc Risk Rep. 2015;9(10).
  146. Levoy E, Lazaridou A, Brewer J, Fulwiler C. An exploratory study of Mindfulness Based Stress Reduction for emotional eating. Appetite. 2017;109:124-130.
  147. Warren JM, Smith N, Ashwell M. A structured literature review on the role of mindfulness, mindful eating and intuitive eating in changing eating behaviours: effectiveness and associated potential mechanisms. Nutr Res Rev. 2017;30(2):272-283.
  148. Schnepper R, Richard A, Wilhelm FH, Blechert J. A combined mindfulness-prolonged chewing intervention reduces body weight, food craving, and emotional eating. J Consult Clin Psychol. 2019;87(1):106-111.
  149. Jacob A, Moullec G, Lavoie KL, et al. Impact of cognitive-behavioral interventions on weight loss and psychological outcomes: A meta-analysis. Health Psychol. 2018;37(5):417-432.
  150. Linardon J, Wade TD, de la Piedad Garcia X, Brennan L. The efficacy of cognitive-behavioral therapy for eating disorders: A systematic review and meta-analysis. J Consult Clin Psychol. 2017;85(11):1080-1094.
  151. Paul L, van der Heiden C, Hoek HW. Cognitive behavioral therapy and predictors of weight loss in bariatric surgery patients. Current opinion in psychiatry. 2017;30(6):474-479.
  152. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. Journal of the American College of Cardiology. 2018;71(1):69-84.
  153. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Jama. 2016;315(22):2424-2434.
  154. Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018;78(11):1113-1132.
  155. Vairavamurthy J, Cheskin LJ, Kraitchman DL, Arepally A, Weiss CR. Current and cutting-edge interventions for the treatment of obese patients. European journal of radiology. 2017;93:134-142.
  156. Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019;7(16):393.
  157. Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. International journal of obesity (2005). 2019;43(10):2085-2094.
  158. Salvatore T, Pafundi PC, Morgillo F, et al. Metformin: An old drug against old age and associated morbidities. Diabetes Res Clin Pract. 2020;160:108025.
  159. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Current obesity reports. 2019;8(2):156-164.
  160. Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes. 2019;10(3):154-168.
  161. Pascale A, Marchesi N, Govoni S, Coppola A, Gazzaruso C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Current opinion in pharmacology. 2019;49:1-5.
  162. Harsch IA, Konturek PC. The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into "Old" Diseases. Med Sci (Basel). 2018;6(2).
  163. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-370.
  164. Solymar M, Ivic I, Poto L, et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. PLoS One. 2018;13(11):e0207947.
  165. Panda SR, Jain M, Jain S, Saxena R, Hota S. Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials. J Obstet Gynaecol India. 2018;68(5):336-343.
  166. Graff SK, Mario FM, Ziegelmann P, Spritzer PM. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. International journal of clinical practice. 2016;70(6):450-461.
  167. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2013;121(1):27-31.
  168. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323-329.
  169. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731-737.
  170. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002;346(6):393-403.
  171. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170(10):682-690.
  172. Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071-1094.
  173. Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of alpha-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert opinion on pharmacotherapy. 2015;16(13):1959-1981.
  174. Zhang M, Feng R, Yang M, et al. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Res Care. 2019;7(1):e000717.
  175. Smith BJ, Miller RA, Ericsson AC, Harrison DC, Strong R, Schmidt TM. Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice. BMC Microbiol. 2019;19(1):130.
  176. Baxter NT, Lesniak NA, Sinani H, Schloss PD, Koropatkin NM. The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome. mSphere. 2019;4(1).
  177. Wang N, Zhang JP, Xing XY, et al. MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin. Archives of medical science : AMS. 2019;15(2):309-320.
  178. Sun W, Zeng C, Liao L, Chen J, Wang Y. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. Current medical research and opinion. 2016;32(8):1389-1396.
  179. Talaviya PA, Saboo BD, Dodiya HG, et al. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes. Diabetes Metab Syndr. 2016;10(2):88-91.
  180. Nakhaee A, Sanjari M. Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2013;18(5):391-394.
  181. Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol. 2007;6:20.
  182. Bonamichi BDSFP, B. E.; dos Santos, B. R.; Beltzhoover, R.; Lee, J.; Nunes Salles, J. E. The Challenge of Obesity: A Review of Approved Drugs and New Therapeutic Targets. J Obes Eat Disord. 2018;4(2).
  183. Thompson CC, Abu Dayyeh BK, Kushnir V, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2019;15(8):1348-1354.
  184. Ruban A, Doshi A, Lam E, Teare JP. Medical Devices in Obesity Treatment. Current diabetes reports. 2019;19(10):90.
  185. Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J. 2011;10:24.
  186. Preuss HG. Bean amylase inhibitor and other carbohydrate absorption blockers: effects on diabesity and general health. J Am Coll Nutr. 2009;28(3):266-276.
  187. Udani J, Tan O, Molina J. Systematic Review and Meta-Analysis of a Proprietary Alpha-Amylase Inhibitor from White Bean (Phaseolus vulgaris L.) on Weight and Fat Loss in Humans. Foods. 2018;7(4).
  188. Moratalla-Lopez N, Bagur MJ, Lorenzo C, Salinas M, Alonso GL. Bioactivity and Bioavailability of the Major Metabolites of Crocus sativus L. Flower. Molecules (Basel, Switzerland). 2019;24(15).
  189. Ghajar A, Neishabouri SM, Velayati N, et al. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. Pharmacopsychiatry. 2017;50(4):152-160.
  190. Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-313.
  191. Foshati S, Ekramzadeh M. Thylakoids: A Novel Food-Derived Supplement for Obesity - A Mini-Review. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2020;90(1-2):169-178.
  192. Montelius C, Erlandsson D, Vitija E, Stenblom EL, Egecioglu E, Erlanson-Albertsson C. Body weight loss, reduced urge for palatable food and increased release of GLP-1 through daily supplementation with green-plant membranes for three months in overweight women. Appetite. 2014;81:295-304.
  193. Stenblom EL, Montelius C, Östbring K, et al. Supplementation by thylakoids to a high carbohydrate meal decreases feelings of hunger, elevates CCK levels and prevents postprandial hypoglycaemia in overweight women. Appetite. 2013;68:118-123.
  194. Rice SP, Zhang L, Grennan-Jones F, et al. Dehydroepiandrosterone (DHEA) treatment in vitro inhibits adipogenesis in human omental but not subcutaneous adipose tissue. Molecular and cellular endocrinology. 2010;320(1-2):51-57.
  195. Jankowski CM, Wolfe P, Schmiege SJ, et al. Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials. Clin Endocrinol (Oxf). 2019;90(2):293-300.
  196. Gomez-Santos C, Hernandez-Morante JJ, Tebar FJ, Granero E, Garaulet M. Differential effect of oral dehydroepiandrosterone-sulphate on metabolic syndrome features in pre- and postmenopausal obese women. Clin Endocrinol (Oxf). 2012;77(4):548-554.
  197. Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3(5):533-542.
  198. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. Jama. 2004;292(18):2243-2248.
  199. Ihler G, Chami-Stemmann H. 7-oxo-DHEA and Raynaud's phenomenon. Med Hypotheses. 2003;60(3):391-397.
  200. Zenk JL, Frestedt JL, Kuskowski MA. HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults. J Nutr Biochem. 2007;18(9):629-634.
  201. Kaiman DS, Colker CM, Swain MA, Torina GC, Shi Q. A randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults. Current Therapeutic Research. 2000;61(7):435-442.
  202. Maret W. Chromium Supplementation in Human Health, Metabolic Syndrome, and Diabetes. Metal ions in life sciences. 2019;19.
  203. Tsang C, Taghizadeh M, Aghabagheri E, Asemi Z, Jafarnejad S. A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity. Clin Obes. 2019;9(4):e12313.
  204. Tian H, Guo X, Wang X, et al. Chromium picolinate supplementation for overweight or obese adults. The Cochrane database of systematic reviews. 2013(11):Cd010063.
  205. Onakpoya I, Posadzki P, Ernst E. Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obes Rev. 2013;14(6):496-507.
  206. Brownley KA, Von Holle A, Hamer RM, La Via M, Bulik CM. A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study. Journal of psychosomatic research. 2013;75(1):36-42.
  207. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids in health and disease. 2008;7:44.
  208. Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CS. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids in health and disease. 2008;7:12.
  209. Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids in health and disease. 2005;4:12.
  210. Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids Health Dis. 2009;8:7.
  211. Egras AM, Hamilton WR, Lenz TL, Monaghan MS. An evidence-based review of fat modifying supplemental weight loss products. Journal of obesity. 2011;2011.
  212. Wan-Loy C, Siew-Moi P. Marine Algae as a Potential Source for Anti-Obesity Agents. Mar Drugs. 2016;14(12).
  213. Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes, obesity & metabolism. 2010;12(1):72-81.
  214. Kim KM, Kim SM, Cho DY, Park SJ, Joo NS. The Effect of Xanthigen on the Expression of Brown Adipose Tissue Assessed by (1)(8)F-FDG PET. Yonsei medical journal. 2016;57(4):1038-1041.
  215. Rothenberg DO, Zhou C, Zhang L. A Review on the Weight-Loss Effects of Oxidized Tea Polyphenols. Molecules (Basel, Switzerland). 2018;23(5).
  216. Turkozu D, Tek NA. A minireview of effects of green tea on energy expenditure. Crit Rev Food Sci Nutr. 2017;57(2):254-258.
  217. Vazquez Cisneros LC, Lopez-Uriarte P, Lopez-Espinoza A, Navarro Meza M, Espinoza-Gallardo AC, Guzman Aburto MB. Effects of green tea and its epigallocatechin (EGCG) content on body weight and fat mass in humans: a systematic review. Nutr Hosp. 2017;34(3):731-737.
  218. Huang J, Wang Y, Xie Z, Zhou Y, Zhang Y, Wan X. The anti-obesity effects of green tea in human intervention and basic molecular studies. European journal of clinical nutrition. 2014;68(10):1075-1087.
  219. Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. The Cochrane database of systematic reviews. 2012;12:Cd008650.
  220. Peluso I, Serafini M. Antioxidants from black and green tea: from dietary modulation of oxidative stress to pharmacological mechanisms. Br J Pharmacol. 2017;174(11):1195-1208.
  221. Okla M, Kim J, Koehler K, Chung S. Dietary Factors Promoting Brown and Beige Fat Development and Thermogenesis. Adv Nutr. 2017;8(3):473-483.
  222. Nicoletti CF, Delfino HBP, Pinhel M, et al. Impact of green tea epigallocatechin-3-gallate on HIF1-alpha and mTORC2 expression in obese women: anti-cancer and anti-obesity effects? Nutr Hosp. 2019;36(2):315-320.
  223. Willems MET, Sahin MA, Cook MD. Matcha Green Tea Drinks Enhance Fat Oxidation During Brisk Walking in Females. International journal of sport nutrition and exercise metabolism. 2018;28(5):536-541.
  224. Preuss HG, Echard B, Bagchi D, Perricone NV. Comparing effects of carbohydrate (CHO) blockers and trivalent chromium on CHO-induced insulin resistance and elevated blood pressure in rats. J Am Coll Nutr. 2013;32(1):58-65.
  225. Osaki S, Kimura T, Sugimoto T, Hizukuri S, Iritani N. L-arabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats. J Nutr. 2001;131(3):796-799.
  226. Seri K, Sanai K, Matsuo N, Kawakubo K, Xue C, Inoue S. L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Metabolism: clinical and experimental. 1996;45(11):1368-1374.
  227. Krog-Mikkelsen I, Hels O, Tetens I, Holst JJ, Andersen JR, Bukhave K. The effects of L-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans. Am J Clin Nutr. 2011;94(2):472-478.
  228. Shibanuma K, Degawa Y, Houda K. Determination of the transient period of the EIS complex and investigation of the suppression of blood glucose levels by L-arabinose in healthy adults. European journal of nutrition. 2011;50(6):447-453.
  229. Jen C, Grunberger, Artiss. On the binding ratio of α-cyclodextrin to dietary fat in humans. Nutrition and Dietary Supplements. 2013;2013:9.
  230. Gallahar DD, Gallahar CM, Plank DW. Alpha-Cyclodextrin selectively increases fecal excretion of saturated fats. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21:2.
  231. Nihei N, Okamoto H, Furune T, et al. Dietary α-cyclodextrin modifies gut microbiota and reduces fat accumulation in high-fat-diet-fed obese mice. BioFactors (Oxford, England). 2018:10.1002/biof.1429.
  232. Sakurai T, Sakurai A, Chen Y, et al. Dietary α-cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E-deficient mice. Molecular nutrition & food research. 2017;61(8):10.1002/mnfr.201600804.
  233. Grunberger G, Jen KLC, Artiss JD. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes/metabolism research and reviews. 2007;23(1):56-62.
  234. Comerford KB, Artiss JD, Jen KLC, Karakas SE. The beneficial effects of α-cyclodextrin on blood lipids and weight loss in healthy humans. Obesity (Silver Spring, Md). 2011;19(6):1200-1204.
  235. Amar MJA, Kaler M, Courville AB, Shamburek R, Sampson M, Remaley AT. Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids. Lipids in health and disease. 2016;15(1):115-115.
  236. Bär A, Diamantis I, Venetz WP. Alpha-Cyclodextrin Attenuates the Glycemic and Insulinemic Impact of White Bread in Healthy Male Volunteers. Foods (Basel, Switzerland). 2020;9(1):E62.
  237. Wang J, Ha TKQ, Shi YP, Oh WK, Yang JL. Hypoglycemic triterpenes from Gynostemma pentaphyllum. Phytochemistry. 2018;155:171-181.
  238. Gauhar R, Hwang SL, Jeong SS, et al. Heat-processed Gynostemma pentaphyllum extract improves obesity in ob/ob mice by activating AMP-activated protein kinase. Biotechnology letters. 2012;34(9):1607-1616.
  239. Novikova DS, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG. AMP-activated protein kinase: structure, function, and role in pathological processes. Biochemistry Biokhimiia. 2015;80(2):127-144.
  240. Park SH, Huh TL, Kim SY, et al. Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): a randomized, double-blind, placebo-controlled trial. Obesity (Silver Spring). 2014;22(1):63-71.
  241. Lee HS, Lim SM, Jung JI, et al. Gynostemma Pentaphyllum Extract Ameliorates High-Fat Diet-Induced Obesity in C57BL/6N Mice by Upregulating SIRT1. Nutrients. 2019;11(10).
  242. Liu J, Li Y, Yang P, et al. Gypenosides Reduced the Risk of Overweight and Insulin Resistance in C57BL/6J Mice through Modulating Adipose Thermogenesis and Gut Microbiota. J Agric Food Chem. 2017;65(42):9237-9246.
  243. Yasueda A, Ito T, Maeda K. Review: Evidence-based Clinical Research of Anti-obesity Supplements in Japan. Immunology, endocrine & metabolic agents in medicinal chemistry. 2013;13(3):185-195.
  244. Park Y, lee HJ, Choi JW, Bae SH, Suh HJ. Anti-diabetic effect of Cyclo-His-Pro (CHP)-enriched yeast hydrolysate in streptozotocin-induced diabetic mice. African Journal of Biotechnology 2013;12:5473.
  245. Nature Education. Glossary. Definition: peptide. http://www.nature.com/scitable/definition/peptide-317. Copyright 2014. Accessed 11/28/2016. Accessed.
  246. Jung EY, Cho MK, Hong YH, et al. Yeast hydrolysate can reduce body weight and abdominal fat accumulation in obese adults. Nutrition (Burbank, Los Angeles County, Calif). 2014;30(1):25-32.
  247. Jung EY, Kim SY, Bae SG, Chang UJ, Choi JW, Suh HJ. WEIGHT REDUCTION EFFECTS OF YEAST HYDROLYSATE BELOW 10 KdA ON OBESE YOUNG WOMEN. Journal of Food Biochemistry. 2011;35:337-350.
  248. Jung EY, Lee JW, Hong YH, Chang UJ, Suh HJ. Low Dose Yeast Hydrolysate in Treatment of Obesity and Weight Loss. Preventive nutrition and food science. 2017;22(1):45-49.
  249. Lee HS, Jung EY, Suh HJ. Chemical composition and anti-stress effects of yeast hydrolysate. Journal of medicinal food. 2009;12(6):1281-1285.
  250. Mansur RB, Brietzke E, McIntyre RS. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neuroscience and biobehavioral reviews. 2015;52:89-104.
  251. Hong KB, Jung EY, Kim JH, chang UJ, Suh HJ. Yeast hydrolysate as a functional anti-obesity ingredient: appetite suppressive effects of yeast hydrolysate in food-deprived mice. Progr Nutr [Internet]. 2015;17:262-264.
  252. CST. Cell Signaling Technology. Protein page: ghrelin (human). http://www.phosphosite.org/proteinAction.action?id=2234200. Copyright 2013. Accessed 11/28/2016. Accessed.
  253. Jung EY, Kang DH, Suh HJ, Chang UJ. Effects of yeast hydrolysate on neuropeptide Y (NPY) and tryptophan hydroxylase (TPH) immunoreactivity in rats. Phytother Res. 2009;23(5):619-623.
  254. Jung EY, Suh HJ, Kim SY, Hong YS, Kim MJ, Chang UJ. Appetite suppressive effects of yeast hydrolysate on nitric oxide synthase (NOS) expression and vasoactive intestinal peptide (VIP) immunoreactivity in hypothalamus. Phytother Res. 2008;22(11):1417-1422.
  255. Jung EY, Hong YH, Park C, Suh HJ. Effects of Cyclo-His-Pro-enriched yeast hydrolysate on blood glucose levels and lipid metabolism in obese diabetic ob/ob mice. Nutrition research and practice. 2016;10(2):154-160.
  256. Jung EY, Lee HS, Choi JW, Ra KS, Kim MR, Suh HJ. Glucose tolerance and antioxidant activity of spent brewer's yeast hydrolysate with a high content of Cyclo-His-Pro (CHP). Journal of food science. 2011;76(2):C272-278.
  257. Jung EY, Hong YH, Kim JH, et al. Effects of yeast hydrolysate on hepatic lipid metabolism in high-fat-diet-induced obese mice: yeast hydrolysate suppresses body fat accumulation by attenuating fatty acid synthesis. Ann Nutr Metab. 2012;61(2):89-94.
  258. Kim KM, Chang UJ, Kang DH, Kim JM, Choi YM, Suh HJ. Yeast hydrolysate reduces body fat of dietary obese rats. Phytother Res. 2004;18(11):950-953.
  259. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001;25(3):316-324.
  260. Bortolin RC, Vargas AR, de Miranda Ramos V, et al. Guarana supplementation attenuated obesity, insulin resistance, and adipokines dysregulation induced by a standardized human Western diet via brown adipose tissue activation. Phytother Res. 2019;33(5):1394-1403.
  261. Lima NDS, Teixeira L, Gambero A, Ribeiro ML. Guarana (Paullinia cupana) Stimulates Mitochondrial Biogenesis in Mice Fed High-Fat Diet. Nutrients. 2018;10(2).
  262. Ovalle-Magallanes B, Eugenio-Perez D, Pedraza-Chaverri J. Medicinal properties of mangosteen (Garcinia mangostana L.): A comprehensive update. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2017;109(Pt 1):102-122.
  263. Galani VJ, Patel BG, Rana DG. Sphaeranthus indicus Linn.: A phytopharmacological review. Int J Ayurveda Res. 2010;1(4):247-253.
  264. Kudiganti V, Kodur RR, Kodur SR, Halemane M, Deep DK. Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects. Lipids Health Dis. 2016;15(1):136.
  265. Stern JS, Peerson J, Mishra AT, Sadasiva Rao MV, Rajeswari KP. Efficacy and tolerability of a novel herbal formulation for weight management. Obesity (Silver Spring). 2013;21(5):921-927.
  266. Stern JS, Peerson J, Mishra AT, Mathukumalli VS, Konda PR. Efficacy and tolerability of an herbal formulation for weight management. Journal of medicinal food. 2013;16(6):529-537.
  267. Bagchi D, Lau FC, Golakoti T, Krishnaraju AV, Sengupta K. Efficacy and Tolerability of Merastin - a Novel Herbal Formulation for Weight Management: A Randomized Double Blind Placebo Controlled Clinical Study. The FASEB Journal. 2011;25(1_supplement):601.609-601.609.
  268. den Hartigh LJ. Conjugated Linoleic Acid Effects on Cancer, Obesity, and Atherosclerosis: A Review of Pre-Clinical and Human Trials with Current Perspectives. Nutrients. 2019;11(2).
  269. Lehnen TE, da Silva MR, Camacho A, Marcadenti A, Lehnen AM. A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism. J Int Soc Sports Nutr. 2015;12:36.
  270. Shen W, McIntosh MK. Nutrient Regulation: Conjugated Linoleic Acid's Inflammatory and Browning Properties in Adipose Tissue. Annu Rev Nutr. 2016;36:183-210.
  271. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ (Clinical research ed). 2017;359:j5024.
  272. St-Onge MP, Salinardi T, Herron-Rubin K, Black RM. A weight-loss diet including coffee-derived mannooligosaccharides enhances adipose tissue loss in overweight men but not women. Obesity (Silver Spring). 2012;20(2):343-348.
  273. Muhammad HFL, Sulistyoningrum DC, Huriyati E, Lee YY, Manan Wan Muda WA. The Interaction between Coffee: Caffeine Consumption, UCP2 Gene Variation, and Adiposity in Adults-A Cross-Sectional Study. J Nutr Metab. 2019;2019:9606054.
  274. Gorji Z, Varkaneh HK, Talaei S, et al. The effect of green-coffee extract supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytomedicine. 2019;63:153018.
  275. Sarria B, Martinez-Lopez S, Sierra-Cinos JL, Garcia-Diz L, Mateos R, Bravo-Clemente L. Regularly consuming a green/roasted coffee blend reduces the risk of metabolic syndrome. European journal of nutrition. 2018;57(1):269-278.
  276. Bendtsen LQ, Lorenzen JK, Bendsen NT, Rasmussen C, Astrup A. Effect of dairy proteins on appetite, energy expenditure, body weight, and composition: a review of the evidence from controlled clinical trials. Adv Nutr. 2013;4(4):418-438.
  277. Dudgeon WD, Kelley EP, Scheett TP. Effect of Whey Protein in Conjunction With a Caloric-Restricted Diet and Resistance Training. Journal of strength and conditioning research / National Strength & Conditioning Association. 2017;31(5):1353-1361.
  278. Stonehouse W, Wycherley T, Luscombe-Marsh N, Taylor P, Brinkworth G, Riley M. Dairy Intake Enhances Body Weight and Composition Changes during Energy Restriction in 18-50-Year-Old Adults-A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2016;8(7).
  279. Lopes Gomes D, Moehlecke M, Lopes da Silva FB, Dutra ES, D'Agord Schaan B, Baiocchi de Carvalho KM. Whey Protein Supplementation Enhances Body Fat and Weight Loss in Women Long After Bariatric Surgery: a Randomized Controlled Trial. Obesity surgery. 2017;27(2):424-431.
  280. Wirunsawanya K, Upala S, Jaruvongvanich V, Sanguankeo A. Whey Protein Supplementation Improves Body Composition and Cardiovascular Risk Factors in Overweight and Obese Patients: A Systematic Review and Meta-Analysis. J Am Coll Nutr. 2018;37(1):60-70.
  281. Wang ZB, Xin SS, Ding LN, et al. The Potential Role of Probiotics in Controlling Overweight/Obesity and Associated Metabolic Parameters in Adults: A Systematic Review and Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM. 2019;2019:3862971.
  282. Sivamaruthi BS, Kesika P, Suganthy N, Chaiyasut C. A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements. Biomed Res Int. 2019;2019:3291367.
  283. Mazloom K, Siddiqi I, Covasa M. Probiotics: How Effective Are They in the Fight against Obesity? Nutrients. 2019;11(2).
  284. Cerdo T, Garcia-Santos JA, M GB, Campoy C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. Nutrients. 2019;11(3).
  285. Borgeraas H, Johnson LK, Skattebu J, Hertel JK, Hjelmesaeth J. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2018;19(2):219-232.
  286. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103.
  287. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107-113.
  288. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr. 2011;2(4):304-316.
  289. Albracht-Schulte K, Kalupahana NS, Ramalingam L, et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem. 2018;58:1-16.
  290. Buckley JD, Howe PR. Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity-a review. Nutrients. 2010;2(12):1212-1230.
  291. Keshavarz SA, Mostafavi SA, Akhondzadeh S, et al. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clinical nutrition ESPEN. 2018;25:37-43.
  292. Zhang YY, Liu W, Zhao TY, Tian HM. Efficacy of Omega-3 Polyunsaturated Fatty Acids Supplementation in Managing Overweight and Obesity: A Meta-Analysis of Randomized Clinical Trials. The journal of nutrition, health & aging. 2017;21(2):187-192.
  293. Varghese S, Kubatka P, Rodrigo L, et al. Chili pepper as a body weight-loss food. International journal of food sciences and nutrition. 2017;68(4):392-401.
  294. Tremblay A, Arguin H, Panahi S. Capsaicinoids: a spicy solution to the management of obesity? International journal of obesity (2005). 2016;40(8):1198-1204.
  295. Whiting S, Derbyshire EJ, Tiwari B. Could capsaicinoids help to support weight management? A systematic review and meta-analysis of energy intake data. Appetite. 2014;73:183-188.
  296. Whiting S, Derbyshire E, Tiwari BK. Capsaicinoids and capsinoids. A potential role for weight management? A systematic review of the evidence. Appetite. 2012;59(2):341-348.
  297. Taghizadeh M, Farzin N, Taheri S, et al. The Effect of Dietary Supplements Containing Green Tea, Capsaicin and Ginger Extracts on Weight Loss and Metabolic Profiles in Overweight Women: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Ann Nutr Metab. 2017;70(4):277-285.
  298. Rigamonti AE, Casnici C, Marelli O, et al. Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides. Nutr Res. 2018;52:71-79.
  299. Galligan JJ. Beneficial actions of microbiota-derived tryptophan metabolites. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2018;30(2).
  300. Namkung J, Kim H, Park S. Peripheral Serotonin: a New Player in Systemic Energy Homeostasis. Molecules and cells. 2015;38(12):1023-1028.
  301. Strasser B, Berger K, Fuchs D. Effects of a caloric restriction weight loss diet on tryptophan metabolism and inflammatory biomarkers in overweight adults. European journal of nutrition. 2015;54(1):101-107.
  302. Hrboticky N, Leiter LA, Anderson GH. Effects of L-tryptophan on short term food intake in lean men. Nutrition Research. 1985;5(6):595-607.
  303. Cavaliere H, Medeiros-Neto G. The anorectic effect of increasing doses of L-tryptophan in obese patients. Eating and weight disorders : EWD. 1997;2(4):211-215.
  304. Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr. 1992;56(5):863-867.
  305. Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 1998;22(7):648-654.
  306. Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm. 1989;76(2):109-117.
  307. Hughes GM, Boyland EJ, Williams NJ, et al. The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial. Lipids in health and disease. 2008;7:6.
  308. Pasman WJ, Heimerikx J, Rubingh CM, et al. The effect of Korean pine nut oil on in vitro CCK release, on appetite sensations and on gut hormones in post-menopausal overweight women. Lipids in health and disease. 2008;7:10.
  309. Park S, Lim Y, Shin S, Han SN. Impact of Korean pine nut oil on weight gain and immune responses in high-fat diet-induced obese mice. Nutrition research and practice. 2013;7(5):352-358.
  310. Park S, Shin S, Lim Y, Shin JH, Seong JK, Han SN. Korean Pine Nut Oil Attenuated Hepatic Triacylglycerol Accumulation in High-Fat Diet-Induced Obese Mice. Nutrients. 2016;8(1).
  311. Le NH, Shin S, Tu TH, et al. Diet enriched with korean pine nut oil improves mitochondrial oxidative metabolism in skeletal muscle and brown adipose tissue in diet-induced obesity. J Agric Food Chem. 2012;60(48):11935-11941.
  312. Modanloo M, Shokrzadeh M. Analyzing Mitochondrial Dysfunction, Oxidative Stress, and Apoptosis: Potential Role of L-carnitine. Iran J Kidney Dis. 2019;13(2):74-86.
  313. Askarpour M, Hadi A, Miraghajani M, Symonds ME, Sheikhi A, Ghaedi E. Beneficial effects of l-carnitine supplementation for weight management in overweight and obese adults: An updated systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacological research : the official journal of the Italian Pharmacological Society. 2020;151:104554.
  314. Coleus forskohlii. Monograph. Alternative medicine review : a journal of clinical therapeutic. 2006;11(1):47-51.
  315. Chiadak JD, Arsenijevic T, Verstrepen K, et al. Forskolin Inhibits Lipopolysaccharide-Induced Modulation of MCP-1 and GPR120 in 3T3-L1 Adipocytes through an Inhibition of NFkappaB. Mediators Inflamm. 2016;2016:1431789.
  316. Badmaev V, Majeed M, Conte A, Parker J. Diterpene Forskolin (Coleus forskohlii, Benth.): A possible new compound for reduction of body weight by increasing lean body mass. NutraCos - Nutraceuticals. 2002;1:6-7.
  317. Henderson S, Magu B, Rasmussen C, et al. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. Journal of the International Society of Sports Nutrition. 2005;2:54-62.
  318. Loftus HL, Astell KJ, Mathai ML, Su XQ. Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial. Nutrients. 2015;7(11):9508-9522.
  319. Taheri S, Zaghloul H, Chagoury O, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477-489.
  320. Salehi B, Berkay Yılmaz Y, Antika G, et al. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019;9(8):356. doi:10.3390/biom9080356
  321. Bobe G, Michels AJ, Zhang W-J, et al. A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations. J Nutr. Published online July 21, 2020. doi:10.1093/jn/nxaa203
  322. Huerta AE, Navas-Carretero S, Prieto-Hontoria PL, Martínez JA, Moreno-Aliaga MJ. Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. Obesity. 2015;23(2):313-321. doi:10.1002/oby.20966
  323. Li N, Yan W, Hu X, et al. Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2017;86(5):680-687. doi:10.1111/cen.13303
  324. Koh EH, Lee WJ, Lee SA, et al. Effects of alpha-lipoic Acid on body weight in obese subjects. Am J Med. 2011;124(1):85.e81-88. doi:10.1016/j.amjmed.2010.08.005
  325. Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2018;37(2):419-428. doi:10.1016/j.clnu.2017.06.002
  326. Kucukgoncu S, Zhou E, Lucas KB, Tek C. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obes Rev. 2017;18(5):594-601. doi:10.1111/obr.12528
  327. Kim NW, Song YM, Kim E, et al. Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2016;31(5):265-274. doi:10.1097/yic.0000000000000132
  328. Ratliff JC, Palmese LB, Reutenauer EL, Tek C. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses. 2015;8(4):196-200. doi:10.3371/csrp.Rapa.030113
  329. Akbari M, Ostadmohammadi V, Tabrizi R, et al. The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab (Lond). 2018;15:39. doi:10.1186/s12986-018-0274-y
  330. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863. doi:10.5114/aoms.2016.58928
  331. Gosselin LE, Chrapowitzky L, Rideout TC. Metabolic effects of α-lipoic acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study. Food Funct. 2019;10(9):5732-5738. doi:10.1039/c9fo00390h
  332. Karkabounas S, Papadopoulos N, Anastasiadou C, et al. Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study. J Med Food. 2018;21(12):1197-1203. doi:10.1089/jmf.2018.0007
  333. Tromba L, Perla FM, Carbotta G, Chiesa C, Pacifico L. Effect of Alpha-Lipoic Acid Supplementation on Endothelial Function and Cardiovascular Risk Factors in Overweight/Obese Youths: A Double-Blind, Placebo-Controlled Randomized Trial. Nutrients. 2019;11(2):375. doi:10.3390/nu11020375